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iRésumé
Les cellules beta pancréatiques sécrètent l’insuline lors d’une augmentation post-prandiale
du glucose dans le sang. Ce processus essentiel est contrôlé par des facteurs physiologiques,
nutritionnels et pathologiques. D’autres sources d’énergie, comme les acides aminés
(leucine et glutamine) ou les acides gras potentialisent la sécrétion d’insuline. Une sécrétion
d’insuline insuffisante au besoin du corps déclanche le diabète. Le rôle que joue
l’augmentation du calcium intracellulaire et les canaux K+/ATP dans la sécrétion d’insuline
est bien connu. Bien que le mécanisme exact de la potentialisation de la sécrétion
d’insuline par les lipides est inconnu, le cycle Glycérolipides/Acides gras (GL/FFA) et son
segment lipolytique ont été reconnu comme un composant essentiel de la potentialisation
lipidique de la sécrétion d’insuline. Le diacylglycérol, provenant de la lipolyse, a été
proposé comme un signal lipidique important d’amplification. Cependant, l’hydrolyse des
triglycérides et des diacylglycérides a été démontrée essentielle pour la sécrétion d’insuline
stimulée par le glucose, en suggérant un rôle du monoacylglycérol (MAG) dans ce
processus.
Dans cette étude, on démontre que la réduction de la sécrétion d’insuline stimulée par le
glucose, lors d’une inhibition de la lipolyse, est restaurée par l’addition de MAG. Dans les
cellules beta pancréatiques, le niveau de MAG augmente en présence des concentrations
élevées du glucose, et également lorsqu’on inhibe l’enzyme MAG hydrolase abhydrolase-6
(ABHD6) avec l’inhibiteur spécifique WWL70.
ii
L’analyse lipidomique a démontré qu’après la stimulation des cellules beta pancréatiques
avec le glucose et aussi avec le WWL70, l’espèce la plus accumulée de MAG était le 1-
stearoylglycérol (1-SG). L’addition de 1-SG, de 1-palmitoylglycérol (1-PG) ou de
WWL70 augmente la sécrétion d’insuline stimulée par le glucose, et cette augmentation est
indépendante de la génération de acides gras à partir de MAG. Cela suggère que le MAG
est un signal lipidique pour la potentialisation de la sécrétion d’insuline stimulée par le
glucose. De plus, la surexpression du gène d’ABHD6 dans les cellules INS832/13 cause
une réduction de la sécrétion d’insuline, due probablement à la diminution des niveaux
intracellulaire de MAG.
Avec le but de comprendre le mécanisme moléculaire impliqué dans la potentialisation de
la sécrétion d’insuline par le MAG, on a bloqué l’action du récepteur vanilloid-1 (TRPV1)
liant le MAG par l’agent pharmacologiste, AMG9810. Le traitement des cellules beta
pancréatique par AMG9810 entraîne une diminution de la potentialisation de la sécrétion
de l’insuline induite par le MAG. Il est a noter que le MAG pourrait activer TRPV1 par
une liaison physique dans la membrane cellulaire interne; ce qui entraînerai l’entrée du
calcium dans la cellule, et ensuite la stimulation de l’exocytose des granules à insuline. En
soutien de cette hypothèse, on a trouvé une diminution du calcium intracellulaire lorsqu’on
traite au AMG9810 des cellules beta pancréatique de rat (provenant des îlots dispersés)
stimulées au glucose et au WWL70.
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L’ensemble des résultats suggère que le MAG est un médiateur de la potentialisation
lipidique de la sécrétion d’insuline stimulée par le glucose. Vu que l’inhibition
pharmacologique d’ABHD6 augmente la sécrétion d’insuline, on pourra conclure que cette
enzyme représente une cible thérapeutique potentielle dans le développement des
médicaments anti-diabétiques, visant une augmentation de la sécrétion d’insuline.
Mots-clés : diabète, sécrétion d’insuline stimulée par le glucose, MAG, ABHD6, TRPV1.
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Abstract
Insulin secretion by the pancreatic -cell in response to post-prandial increase in blood
glucose levels is an essential physiological process that is governed by cellular, nutritional
and pathological factors. Other fuels including amino acids like leucine and glutamine and
also fatty acids contribute to further augment insulin secretion. Failure to secrete adequate
amount of insulin according to the changing demands of the body by -cell is a key
determinant of diabetes. The role played by the elevated Ca2+ influx and K+-ATP channels
in insulin secretion is well known. Even though the precise mechanism of the lipid
amplification of insulin secretion and the involved molecular signals are not clear,
Glycerolipid/Free fatty acid (GL/FFA) cycle and its lipolytic segment have been recognized
as essential components in the lipid amplification pathway of insulin secretion.
Diacylglycerol produced by lipolysis was proposed as an important lipid amplification
signal. However, hydrolysis of triglycerides and also of diacylglycerols is shown to be
essential for glucose stimulated insulin secretion (GSIS), indicating a possible role for
monoacylglycerol (MAG) in this process.
In the present study we demonstrate that the obliterated GSIS due to lipolysis inhibition in -
cells can be restored by providing exogenous MAG. In the -cells MAG levels increase
significantly in the presence of high glucose concentration and specific inhibition of the
major MAG hydrolase, abhydrolase-6 (ABHD6), in -cells and islets with WWL70 leads to
accumulation of MAG with concomitant increase in insulin secretion. Lipidomics analysis
vindicated that the major MAG species that is elevated by high glucose as well as WWL70
addition is 1-stearoylglycerol (1-SG). Exogenously added 1-SG and also 1-palmitoylglycerol
(1-PG) strongly enhanced GSIS and this augmentation is not dependent on the generation of
FFA by these MAGs. This indicates that MAG is a potential candidate for being the lipid
signal for GSIS amplification. Further evidence for this was provided by the observation that
overexpression of the MAG hydrolase ABHD6 in INS832/13 cells, resulted in decreased
insulin secretion, probably owing to the lowered MAG level inside the -cells.
Pharmacological studies using AMG9810, a specific antagonist of transient receptor
potential vanilloid-1 (TRPV1) receptor that binds MAG, revealed that a blockade of TRPV1
strongly attenuated the MAG-augmented insulin secretion. Since MAG is a potential
activator of TRPV1, it is likely that MAG binds on the inner surface of the cell membrane to
TRPV1, which in turn triggers rapid influx of Ca2+ thereby promoting insulin granule
exocytosis. Thus, AMG9810 was found to lower Ca2+ influx into dispersed rat islet cells that
was induced by high glucose and also WWL70.
These results collectively suggest that MAG is the potential mediator of the lipid
amplification of glucose-stimulated insulin secretion. Our results also indicate that
pharmacological intervening at the ABHD6 hydrolysis step enhances insulin secretion; this
enzyme protein can be a promising thrapeutic target for the development of anti-diabetic
drugs that promote insulin secretion.
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1. Introduction
1.1 Obesity and Diabetes
1.1.1 The current situation in the world
Economic development and industrialization in many countries offer a wide variety of
choice of foods to people. This has led more and more people to choose foods with elevated
levels of saturated fatty acids, sugar-sweetened beverages and starchy food and reduced
consumption of fibre. In conjunction with more sedentary lifestyle of people the energy
from food intake has often considerably surpassed the daily energy expenditure. The
surplus energy is predominantly stored as fat in the adipocytes and other tissues, therby
contributing to obesity among these people and this is particularly marked for individuals
who are genetically predisposed to obesity (Alappat and Awad, 2010).
Obesity has become a major socio-economic problem all over the world, especially in the
developed countries. According to the American Obesity Association, nealy one third of
the total US population is affected by obesity with a similar situation in Canada. A report
from the National Diabetes Surveillance System indicated that approximately 25% of all
Canadian adults are obese as are 10% of the children (Anis et al., 2010).
The global obesity epidemic is a primary cause for the increasing world-wide incidence of
diabetes in the recent years. According to the World Health Organization and the
International Diabetes Federation, the number of diabetes patients has increased from 100–
135 million in 1994–1995 to approximately 246 million in 2007, worldwide. With a further
37 million people developing diabetes each year, this number is expected to hit 438 million
by 2030. In Canada, approximately 1.9 million men and women had been diagnosed with
diabetes in 2005-2006, which represents about 1 in 17 Canadians - 5.5 % of all women and
6.2 % of all men. And now in 2010, more than 9 million Canadians live with undiagnosed
or diagnosed diabetes, or prediabetes.
Diabetes is defined in simple terms, as the pathological situation where inadequate amount
of insulin is secreted to meet the needs of body, with the resultant hyperglycemia, the
hallmark of diabetes. However, diabetes is a highly complex metabolic disorder with a
multitude of mechanisms for its causes, including both genetic and environmental factors
depending on different types of diabetes. Diabetes, on the basis of its causes, could be
divided into three major types- type 1 diabetes (T1D), type 2 diabetes (T2D) and
gestational diabetes as well as other types, such as permanent neonatal diabetes (Gloyn et
al., 2004).
1.1.2 Type 1 Diabetes (T1D)
T1D that is also named Juvenile diabetes, accounts for about 5 -10% of all cases of diabetes.
In the United-States, 1 million people have been diagnosed with T1D in 2000. There are
potentially another million patients, mostly adults, who have been possibly misdiagnosed as
having type 2 diabetes (Prevalence of Diabetes in the United States based on US Population:
4275 million in 2000). Additional studies predict that the incidence of T1D may be
increasing at a rate of 3 - 4% a year (Dahlquist, 1998; Gloyn et al., 2004).
Type 1 diabetes is in the vast majority of its cases a chronic autoimmune disease, in which
T cells and macrophages invade pancreatic islets and specifically target and kill beta cells
in genetically predisposed individuals causing near complete loss of insulin secretion with
the resultant hyperglycemia (Sera et al., 1999; Winter, 1996); At present, the exact
mechanisms underlying the causes whereby the body's immune system is triggered to
attack the beta cells is still not well understood. Some studies indicated that autoimmune,
genetic, and environmental factors, possibly viruses, are involved in this process. Generally,
T1D most often affects children and young adults, but can also appear at any age.
Symptoms include increased thirst and urination, constant hunger, weight loss, blurred
vision, and extreme fatigue. If not treated with insulin, a person with type 1 diabetes can
lapse into a life-threatening diabetic coma, also known as diabetic ketoacidosis. Although
the symptoms of T1D generally develop within a short period, the beta cell destruction
maybe occurring over the span of several years prior the development of overt T1D. Thus,
this allows for the possible prevention of T1D transition to overt diabetes. More than 30
years ago, it was observed that certain antibodies (named as islet cell antibodies) in TID
patients could specifically bind to pancreatic islets. Presently, three major autoantigens:
glutamic acid decarboxylase (GAD65) (Baekkeskov et al., 1989), a protein tyrosine
phosphatase-like molecule (IA-2) (Notkins et al., 1996) and insulin (Palmer, 1987) have
been identified. Using assays that employ islet cell autoantibodies, it is possible to
5accurately identify people at higher risk for T1D. Once the risk is identified, these people
can have time to use different strategies to delay or prevent the incidence of T1D, such as
taking oral insulin capsules (Skyler et al., 2005). For people who are already suffering with
T1D, the secure and relatively convenient way is to treat the disease by daily administration
of insulin, because presently there is no “cure” for T1D. Even though islet transplantation
has shown to be a promising therapy for T1D for many years (Gruessner et al., 2004;
Rickels et al., 2006), it is not widely used due to its high price, graft immuno-suppression
associated problems, and limitation of islet donors. Another promising strategy for T1D is
the regeneration of beta cells from stem cells, precursor cells or the remaining beta cells
(Meier et al., 2005). Thus, murine adult pancreatic precursor cell likely exists that could
differentiate into cells with the characteristics of ¦Âcells (Seaberg et al., 2004). Another
study showed that the prinicipal source of new beta cells is from the pre-existing beta cells,
rather than pluripotent stem cells (Dor et al., 2004).
1.1.3 Gestational diabetes
Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance that is
first detected during pregnancy (Jovanovic et al., 1998). According to the American
Diabetes Association (ADA), about 7% of all the pregnancies in USA are diagnosed with
having GDM (Simmons et al., 2010). Another report indicates that the total incidence of the
GDM can be as high as 17.8% (Metzger et al., 2010). Once diagnosed with GDM, the
mother as well as its offspring, who has been exposed to hyperglycemic intrauterine
6environment, has increased risk of developing type 2 diabetes mellitus in the future
(Bellamy et al., 2009; Clausen et al., 2008). Because of the lack of uniform diagnostic
criteria (Karagiannis et al., 2010), the global incidence of GDM is difficult to estimate. But
it is well-accepted that GDM is a common disorder in pregnancy (Yogev et al., 2004).
The mechanism related to incidence of GDM has not been fully elucidated, but at least
three different factors have been shown to be implicated in this process: 1) auto-immune
destruction of beta cell; 2) genetic abnormalities leading to defective insulin secretion; 3)
beta cell dysfunction related to insulin resistance. As a consequence, the incidence of GDM
is not only influenced by environmental factors, but also by genetic factors, and it shares
some similarities to both T1D and T2D. So treatment of GDM may be different based on
the individuals. The importance of nutrition in the management of GDM is well established
(Amann-Gassner and Hauner, 2008). Since glucose is the primary fuel for the fetus and the
characteristic of GDM is hyperglycemia, a healthy pregnancy outcome has to be met in the
context of aberrant regulation of glucose metabolism. The main objective of nutritional
recommendation for women with GDM is to maintain maternal normoglycemia and to
reduce inadvertent accelerated fetal growth. The dietary advises are expected to have a
lifelong positive impact for women with GDM so that maternal health is maintained and
the risk for developing type 2 diabetes mellitus in the future is alleviated.
1.1.4 Type 2 diabetes (T2D)
7T2D is characterized with inadequate insulin secretion by pancreatic beta cells leading to
hyperglycemia in individuals with a long history of insulin resistance and is predominantly
due to the dysfunction of beta cells. T2D is thought to be a complex syndrome of polygenic
nature (Fig 1) and many genes, such as CAPN10, ENPP1, HNF4A, ACDC, SLC308A,
IDE-KIF11, EXT2-ALX4 that contribute to the development of T2D have been identified
(Perry and Frayling, 2008; Sladek et al., 2007) with the help of the new high-density array
technology that permits the simultaneous genotyping of thousands of polymorphisms.
Some of the identified susceptible genes, such as zinc transporter SLC308A, are
exclusively expressed in beta cells (Potapov et al., 2010). Many other genes that are also
related to T2D still need to be identified. Discovery of new T2D risk genes will help in
identifying novel players in T2DM pathogenesis, and will unravel novel mechanisms and
lead to more efficient therapeutics.
8Figure 1 The possible causal factors of T2D. The onset of T2D is complex, not only
related to the environmental factors, such as change of life style, but also the genetic
background. Several risk factors have been linked with onset of T2D and four factors,
including life style, decreased insulin secretion, altered CNS signaling and genetic
predisposition shown in red arrow play crucial roles in T2D.
T2D is the more common type of diabetes and accounts for approximately 90 to 95 percent
of all cases of diabetes. Approximately 150 million people worldwide were affected by
T2D in the year 2000 but this number has climbed to ~250 million in 2010. According to
the Canadian Diabetes Association, it is estimated that nearly 3 million Canadians suffer
from T2D in 2010. Because of the global obesity epidemic and increasing number of
9people with insulin resistance, it is predicted that this number could increase to 370 million
by 2030. Incidence of T2D is strongly associated with older age, obesity, family history of
diabetes, previous history of gestational diabetes, physical inactivity and ethnicity (Al-
Adsani et al., 2009). There has been an alarming increase in childhood obesity associated
with T2D (Amed et al., 2010). However, nationally representative data on prevalence of
type 2 diabetes in youth are not available.
Unlike T1D, the symptoms of type 2 diabetes develop gradually. T2D is actually
considered as a syndrome rather than a disease such as anemia and hypothyroidism. Even
though there are no overt symptoms for T2D such as fever, pain etc., if the hyperglycemia
of these patients is not corrected soon with pharmacological, nutritional or physical
intervention, gradually the function of several organs, such as kidney, foot as well as eyes
and brains, can be compromised. Thus untreated T2D can become a serious health and
social problem due to secondary complications (Renard, 2009), affecting the quality of life
and even threatening life. Even though our knowledge related to the onset of T2D is still
poor, some crucial factors have been identified and proven to be implicated. Numerous
studies show that most individuals with T2D have insulin resistance (Lillioja et al., 1993;
Prentki and Nolan, 2006) and more importantly, insulin resistance appears before the
development of hyperglycemia in subjects that eventually develop T2D (Martin et al., 1992;
Prentki and Nolan, 2006). Furthermore, it is now recognized that T2D develops in insulin-
resistant subjects with the onset of beta cell dysfunction (Prentki and Nolan, 2006). So
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insulin resistance and beta cell dysfunction are two crucial factors that play significant role
in the onset of T2D as shown in Fig 2.
Figure 2 Islet beta cell failure and natural history of T2D. T2D develops in response to
overnutriton and lack of physical activity in subjects that have underlying genetic and
acquired predispositions to both insulin resistance (and/or hyperinsulinemia) and beta cell
dysfunction. Over time, islet beta cell compensation for the insulin resistance fails,
resulting in a progressive decline in -cell function. As a consequence, subjects progress
from normal glucose tolerance (NGT) to IGT and finally to established T2D. Even after
diagnosis of T2D, -cell function continues to worsen such that subjects progress from
needing changes in diet/exercise only to requiring oral hypoglycemic agents and eventually
insulin for achievement of adequate glycemic control. Future therapies will be directed not
only to achievement of euglycemia, but also changing the course of the disease by
reversing the processes of -cell failure (Nolan et al., 2006b).
1.1.4.1 Insulin resistance
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Insulin sensitivity is commonly described as the ability of insulin to lower plasma glucose
levels by suppressing hepatic glucose production and stimulating glucose utilization in
skeletal muscle and adipose tissue (Fujimoto, 2000). Reduced insulin sensitivity makes the
insulin-target tissues to respond poorly to insulin, leading to insulin resistance, which is an
important link between obesity and T2D. Development of insulin resistance depends both
on inherited and acquired factors. The inherited factors are most evident in the off-springs
of T2D, who have more chance to be affected by insulin resistance (Warram et al., 1990).
Some inherited defects have been identified, such as mutations in insulin receptors, glucose
transporters and signaling proteins, but these mutations are relatively rare, and cannot
explain the most common forms of insulin resistance, which is usually closely related to
T2D. More work needs to be done to identify these inherited defects. With regard to the
acquired causes of insulin resistance, some of the responsible factors include less physical
activity, fuel surfeit, aging, hyperglycemia, hyperlipidemia and high level of plasma free
fatty acids (FFA) as well as some medications. The mechanisms whereby these factors lead
to insulin resistance are largely unknown. Some evidences indicate that impaired insulin
signal transduction may be responsible. Insulin signaling involves a cascade of events
initiated by insulin binding to its cell surface receptor, followed by receptor
autophosphorylation, and activation of receptor tyrosine kinases, which result in tyrosine
phosphorylation of insulin receptor substrates (IRSs)(Choi and Kim, 2010). IRSs further
activate phosphatidylinositol 3-kinase (PI3K) and as a consequence, Akt will be activated
and then phosphorylate its downstream targets, such as AS 160, which is implicated in the
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process of glucose transport. IRS-1/PI3K/Akt signaling pathway is crucial in the regulation
of glucose transport in response to insulin in skeletal muscle, the major site of glucose
disposal (Koopmans et al., 1997). Loss of insulin signaling leads to severe insulin
resistance in hepatocytes and progressive liver dysfunction (Pessin and Saltiel, 2000).
Restoration of IRS-1/PI3K/Akt signaling pathway using insulin-sensitizer agents, such as
metfomin, troglitazone and other thiazolidinediones could reverse insulin resistance and
delay, or even prevent the onset of T2D. Interestingly, a polymorphism associated with
T2D has been found within the IRS1 gene locus (Rung et al., 2009).
Insulin resistance is closely related to lipid metabolism. FFA derived from lipid metabolism
(both do novo synthesis and lipolysis) is an important inducer of insulin resistance. From
one side, high levels of FFA could directly interrupt the insulin signaling and decreased
plasma membrane translocation of Glut4 in muscle and therefore lead to lower glucose
disposal (Boden et al., 1991). Decreasing the FFA level in obese nondiabetic individuals is
helpful to ameliorate insulin sensitivity in skeletal muscle (Santomauro et al., 1999). Blood
levels of FFA are influenced by dietary intake and also by contributions from lipolysis of
depot fats in adipose and other tissues. Adipose tissue triglyceride lipase (ATGL) is an
important enzyme in lipolysis and its deficiency leads to TG accumulation and decreased
FFA release, as a result, increasing insulin sensitivity and glucose tolerance (Hoy et al.,
2010). On the other hand, increased level of FFA causes DAG and ceramide accumulation
and DAG has been shown to disrupt normal insulin signaling by serine phosphorylation of
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IRS1, through the activation of some atypical protein kinase C isoforms (Itani et al., 2002).
Ceramides could activate protein phosphatase 2A, leading to dephosphorylation of Akt,
thereby blocking insulin signaling and inhibiting Glut4 translocation to the cell membrane,
thus disrupting insulin-mediated glucose uptake into skeletal muscle (Bonen et al., 2004).
Besides the level of circulating FFA, intracellular content of FFA is also an important
determinant of insulin resistance that acts independently of cellular energy balance and
stress (Matsuzaka et al., 2007). Additional metabolic signaling pathways that could be
central to insulin resistance are the AMP-kinase/malonyl-CoA signaling network and the
glycerolipid/FFA cycle. Thus, elevated glucose and FFA will lead to AMPK inhibition,
acetyl-CoA carboxylase activation and enhanced malonyl-CoA accumulation leading to
reduced FFA oxidation and a rise in DAG that can activate C-kinase enzyme and thus cause
reduced insulin signaling (Prentki and Corkey, 1996; Ruderman and Prentki, 2004). The
evidence has been reviewed recently that altered GL/FFA cycling, with resulting
accumulation of particular GL, such as DAG, MAG and phosphatidate, is implicated in
insulin resistance and tissue malfunction during fuel surfeit (Prentki and Madiraju, 2008).
Besides FFA, Sphingolipids metabolism, such as glucosylceramides are also implicated in
the pathogenesis of insulin resistance. It has been shown that pharmacological inhibition or
genetic ablation of enzymes controlling sphingolipid synthesis in rodents ameliorates
insulin resistance (Holland and Summers, 2008; Summers and Nelson, 2005).
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It is widely accepted that insulin resistance plays crucial role in pathogenesis of T2D and
other diseases associated with the metabolic syndrome. Amelioration of insulin resistance
is necessary to delay or prevent the onset of T2D. Some evidence showed that angiotensin-
converting-enzyme inhibitors could prevent the onset of T2D (Solski and Longyhore, 2008).
And also physical activity could improve insulin sensitivity and glucose tolerance in the
skeletal muscle, and therefore it is also a good measure to prevent T2D. Certainly, our
current knowledge related to insulin resistance is not enough to prevent T2D. More efforts
are needed to completely understand the molecular mechanisms, and to find better
treatments to prevent and cure insulin resistance and T2D.
1.1.4.2 Beta cell dysfunction
Beta cell is the only cell that synthesizes insulin and is responsible for insulin release,
which plays key role in glucose homeostasis. Multiple evidences indicate that beta cell
dysfunction is present in individuals with T2D and acts as an integral part in the
pathogenesis of T2D. The identified mechanisms responsible for beta cell dysfunction
include glucotoxicity, lipotoxicity, glucolipotoxicity, inflammation and ER stress. We will
separately introduce these different aspects.
1.1.4.2.1 Glucotoxicity
Glucose toxicity for beta cells is defined as dysfunction induced by the exposure of these
cells to chronically high concentrations of glucose, which causes impaired glucose-
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stimulated insulin secretion and insulin gene expression as well as apoptosis under some
conditions (Gleason et al., 2000). After chronic high glucose treatment, beta cell lines, such
as HIT-T15 and INS-1 have reduced glucose-stimulated insulin secretion and also reduced
insulin content (Olson et al., 1993). Studies showed that the insulin promoter activity and
pancreas-duodenum homobox-1 (PDX-1) and MafA binding activity to the insulin
promoter also decreased (Olson et al., 1993; Olson et al., 1995). Similar results have been
obtained in rat islets cultured ex vivo for up to six weeks (Briaud et al., 1999).
The mechanism regarding glucose toxicity is closely related to the remodeling of glucose
metabolism in the beta cell. Instead of glucose being metabolized via glycolysis to produce
pyruvate that enters the Krebs’ cycle, additional pathways are activated that include
glyceraldehyde autooxidation, lipogenesis with DAG formation and PKC activation,
sorbitol metabolism leading to the accumulation of reactive oxygen speices (ROS) (Poitout
and Robertson, 2002). Due to poor defense mechanisms against ROS in the beta cells (low
expression of superoxide dismutases and virtually no expression of catalase or glutathione
peroxidase) ROS eventually cause beta cell dysfunction. Interestingly, beta-cell specific
overexpression of glutathione peroxidase preserves intranuclear MafA and reverses
diabetes in db/db mice (Harmon et al., 2009).
By virtue of glucotoxicity leading to oxidative stress, some antioxidants may be beneficial
in protecting beta cell from this insult. This hypothesis has been supported in studies using
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the anti-oxidants N-acetylcysteine and aminoguanidine. In the Zucker Diabetic Fatty (ZDF)
rats, treatment with these antioxidants has been shown to decrease markers of oxidative
stress and improve glycemia in this T2D model (Briaud et al., 1999). In db/db mice,
treatment with N-acetylcysteine enhanced insulin secretion, ameliorated glycemia, reduced
apoptosis and increased beta cell mass (Kaneto et al., 1999).
1.1.4.2.2 Lipotoxicity
The concept of lipid toxicity derived from the phenomenon that T2D is commonly linked
with elevated levels of triacylglycerol (TG) and FFA in the plasma. Similar to glucotoxicity,
lipotoxocity refers to chronically elevated level of FFA eventually causing beta cell
dysfunction (Gremlich et al., 1997). Different fatty acid species have differential effect in
inducing beta cell apoptosis. Saturated fatty acids, such as palmitate and stearate have
strong effect in inducing cell apoptosis. By contrast, un-saturated fatty acids, such as oleate,
have been shown to protect beta-cells from apoptosis (Cnop et al., 2001; El-Assaad et al.,
2003; Maedler et al., 2003; Morgan et al., 2008). And this protective effect may be due to
the strong ability of unsaturated fatty acid in inducing TG synthesis (Cnop et al., 2001). But
this conclusion has been under debate, as other results indicate the protective effect is due
to reasons other than the metabolism of FFA (Morgan et al., 2008).
Even though the concept of lipotoxicity has been there for many years, it is still short of
strong experimental support. Our and other people’s results indicate that FFA can induce
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beta cell dysfunction only in combination with elevated levels of glucose. In the presence
of low glucose, high FFA (at reasonable concentrations) does not change both in vitro and
in vivo the total insulin content of the ß-cell and only slightly affects glucose-stimulated
insulin secretion. So from this standpoint, the concept of glucolipotoxicity (Prentki et al.,
1998), combination of chronic effect of both high glucose and FFA, is more reasonable to
explain the toxic effect of FFA in beta cells and therefore gained more focus in recent
research.
1.1.4.2.3 Glucolipotoxicity
Glucolipotoxicity is a combination of glucotoxicity and lipotoxicity, but importantly
incorporates the concept of synergy of the toxicity of these fuels when present in excess
simultaneously. This concept has been initially advanced advanced by our lab together with
Dr B Corkey (Prentki and Corkey, 1996) and has been widely accepted. Glucolipotoxicity
indicates the synergistic effects in chronic effect of glucose and fatty acid in inducing beta
cell dysfunction, and therefore glucolipotoxicity shows some similar features as
glucotoxicity, such as decreased glucose-stimulated insulin secretion and decreased total
insulin content of beta cells. Glucolipotoxicity also induces beta cell dysfunction in a
unique fashion. When INS832/13 cells, derived from rat beta cells were incubated in
different conditions with high glucose (20mM glucose, no FFA), or high FFA (0.4mM
palmitate, 5mM glucose), or high glucose (20mM) plus high FFA (0.4mM), high FFA
alone has no effect in comparison to high glucose, indicating only high FFA per se has no
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toxic effect. Of special importance, the combination of high glucose and high FFA showed
highest apoptosis, compared to the group with low glucose (El-Assaad et al., 2003). Further
study indicates that this strong apoptosis inducing effect was closely related to lipid
esterification processes, TG accumulation and ceramide deposition as well as activation
cascade-3 pathway in the cells (El-Assaad et al., 2010). Similar results were also reported
in dispersed rat and human islets (Buteau et al., 2004). Some in vivo results also favor the
concept of glucolipotoxicity. A 72 h infusion of glucose and intravenous fat emulsion in 6-
month-old rats leads to insulin resistance and reduced insulin secretion in vivo. This was
associated with diminished glucose-stimulated second-phase insulin secretion and
proinsulin biosynthesis and lower insulin content as well as reduced expression of typical
beta cell genes in isolated islets (Fontes et al., 2010).
The mechanisms related to glucolipotoxicity are strongly associated with glucose and FFA
metabolism. As proposed by our lab, glucose functions as the main determinant of fatty
acid partitioning inside the beta cells. When glucose concentration is in the low to normal
range, fatty acids are transported into mitochrondria through CPT-1, for beta oxidation
without causing any toxic effect. When glucose and fatty acids are both in elevated
concentration, glucose is converted to citrate through TCA cycle and then leads to the
synthesis of malonyl-CoA, which inhibits CPT-1 activity. Inhibition of beta oxidation, at
the CPT-1 step causes fatty acid partitioning from beta oxidation to esterification. High
glucose also leads to enhanced lipolysis, and if the rates of esterfication and lipolysis are
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the same, there is little toxic effect even in the presence of high glucose and high fatty acid.
But if these rates of esterfication and lipolysis are not balanced, many lipid derivatives may
accumulate and induce beta cell dysfunction (Poitout and Robertson, 2008; Prentki et al.,
2002; Prentki and Madiraju, 2008).
1.1.4.2.4 Endoplasmic reticulum (ER) stress
The main function of pancreatic beta cell is insulin synthesis according to the body’s
demand. As estimated, beta cell can produce 18-75 pg insulin per minutes per islets under
basal conditions. This large amount underscores the special “insulin factory” characteristic
of beta cells with a highly developed ER, which is the major site responsible for post-
translational modification, folding and assembly of newly synthesized secretory proteins,
and a cellular calcium store. ER is also an organelle that controls cell survival. A myriad of
pathological and physiological factors, such as impairment of protein transport from the ER
to the Golgi, and calcium depletion from the ER lumen, can compromise the function of the
ER, termed as ER stress (Laybutt et al., 2007). Beta cells have to employ certain
cytoprotective mechanisms to mitigate ER stress, referred to as the unfolded protein
response (UPR), also named as ER stress signaling, that is elicited by ER stress (Eizirik and
Cnop, 2010). The UPR can reduce ER stress and maintain ER function to produce and
process proper amounts of proteins. In the event that the UPR cannot maintain ER
homeostasis, cells activate at least three apoptosis pathways to induce cell apoptosis (Kim
et al., 2006): the transcriptional induction of the genes for CHOP (C/EBP homologous
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protein)/ GADD153 pathway (Oyadomari and Mori, 2004), the c-JUN NH2-terminal
kinase (JNK) pathway (Kaneto et al., 2005), and the ER-localized cysteine protease
caspase-12 pathway (Shiraishi et al., 2006),. Multiple studies have shown that ER stress is
implicated in beta cell apoptosis and may be responsible for the reduction of beta cell mass
in individuals with T2D.
Three ER membrane-associated proteins, inositol requiring 1 (IRE1), PKR-like kinase
(PERK), and activating transcription factor 6 (ATF6) (Yoshida, 2007), have been identified
as master regulators in ER stress signaling and shown to regulate glucose homeostasis.
Pancreatic beta cells deficient in PERK are more susceptible to ER stress-induced apoptosis.
And PERK-deficient mice develop severe hyperglycemia soon after birth in virtue of
defects in islet proliferation and increased apoptosis (Harding et al., 2001).
However, our understanding of the UPR in beta-cells is far from complete. The complexity
of UPR pathways as well as its master regulators has not been completely investigated. We
need to identify the cross talk between UPR pathway and other signaling pathways, such as
mTOR, which have been shown to decrease ER stress (Qin et al., 2010), and also focus on
identifying endogenous molecules and chemical compounds that could modulate ER stress
and protecting beta cells from metabolic stress-induced apoptosis.
1.1.4.2.5 Inflammation
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It has been recognized that cytokines are one of the main “players” in inducing T1D
(Mandrup-Poulsen et al., 1996). The main types of cytokines are interleukin-1beta (IL-
1beta), tissue necrosis factor 1alpha and interferon-¦Ã. But the role of cytokines in the
pathogenesis of T2D is still under debate. It has been reported that high glucose can induce
human islets to produce IL-1beta, which causes beta cell dysfunction (Donath et al., 2003).
But these results could not be reproduced by others. Most recently, it has been shown in a
clinical trial that a drug blocking binding of IL-1beta to its receptor improved beta cell
function and ameliorated the hyperglycemia in human T2D, indicating the important roles
of IL-1beta exerting negative effects on beta cells (Mandrup-Poulsen et al., 2010). However,
large-scale clinical studies in human T2D should be conducted to confirm these results.
1.2 Insulin secretion
As indicated in the first chapter, despite the huge variations in beta cell dysfunction in each
individual affected with diabetes, the common hallmark for all types of diabetes is
hyperglycemia, due to insufficient insulin secretion after stimulation. Insulin was
discovered by Banting and Best in 1922 and its primary structure was deduced in 1951 by
Fred Sanger, who was awarded the Nobel Prize (Sanger, 2001). Insulin is composed of two
polypeptide chains referred to as the A chain and B chain, which are linked together by two
disulfide bonds, and an additional disulfide is formed within the A chain. In most species,
the A chain consists of 21 amino acids and the B chain of 30 amino acids. Although the
amino acid sequence of insulin varies among species, certain segments of the molecule are
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highly conserved, including the positions of the three disulfide bonds, both ends of the A
chain and the C-terminal residues of the B chain. These similarities in the amino acid
sequence of insulin lead to a three dimensional conformation of insulin that is very similar
among different species, and thus insulin from one animal is very likely biologically active
in other species.
1.2.1 Insulin biosynthesis and insulin exocytosis
Insulin biosynthesis is a complex process and involves the formation of several
intermediates, including preproinsulin, proinsulin and other intermediate cleavage products
(Halban, 1991). The initial precursor of insulin from translation of insulin mRNA is
preproinsulin, which is synthesized as a single peptide in the cytoplasm and contains a
characteristic signal peptide with hydrophobic N-terminal 24 amino acid residues. This
signal peptide can be recognized by the signal recognition particle (SRP) (Egea et al., 2005)
and then cotranslationally translocated into the lumen of the ER. Then the signal peptide of
preproinsulin is cleaved by a specialized signal peptidase located on the inner surface of the
rough ER membrane (Patzelt et al., 1978) and produces proinsulin with three disulfide
bonds to stabilize the structure. The ER is an important site for insulin biosynthesis and the
folding of newly synthesized proinsulin. IRE1a, an ER-resident protein kinase, has a crucial
function in insulin biosynthesis. IRE1a phosphorylation is coupled to insulin biosynthesis
in response to transient exposure to high glucose; inactivation of IRE1a signaling by siRNA
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or inhibition of IRE1a phosphorylation inhibits insulin biosynthesis (Lipson et al., 2006).
After the formation of properly folded proinsulin, it is then transported into the Golgi
apparatus for packaging into secretory granules, where the mature insulin is produced.
Convertases are responsible for conversion of proinsulin to insulin in the secretory granules.
At least two convertases, named PC2 and PC1/3 have been identified in the beta cells.
Using immunostaining, PC2 and PC1/3 have been shown to colocalize with proinsulin,
indicating its role in cleavage of proinsulin (Ugleholdt et al., 2006). The difference between
PC2 and PC1/3 is the cleavage site in the proinsulin. PC2 specifically cleaves the proinsulin
at the A-chain junction, and PC1/3 is shown to cleave B-chain junction. After cleavage, the
final products are equal amount of mature insulin and C-peptide, and therefore, C-peptide is
a good indicator of insulin secretion and insulin stability.
Calcium and Zinc play important roles in regulating insulin biosynthesis. By pulse-chase
radiolabelling of isolated rat islets of Langerhans, it has been shown that the Ca2+ ion is
required for prohormone processing in the granules. Depletion of calcium from ER inhibits
the conversion of proinsulin to insulin (Guest et al., 1997). Zinc co-crystallizes with insulin
in dense core secretory granules. Cellular zinc homeostasis is largely maintained by zinc
transporters and intracellular zinc binding proteins. Over-expression of zinc transporter 7
(ZnT7) in beta cells leads to an increase of insulin mRNA expression and subsequent
insulin protein synthesis in the cells by modulating Mtf1 transcriptional activity (Huang et
al., 2010). Using Zinc transporter-8 (ZnT8) deficient mice, ZnT8 was shown to be essential
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for the formation of insulin crystals and the efficient packaging of insulin in beta cells
(Lemaire et al., 2009).
The mature insulin is stored in secretory granules, and awaits the signal to release the
hormone into the blood. The release process is referred as insulin exocytosis. Insulin
vesicle exocytosis is a complex process involving many steps, including vesicle movement,
docking, priming, and finally fusion with the plasma membrane and each step requires
careful regulation in order to release appropriate amounts of insulin in response to
diffevarious stimuli. In order to easily explain the vesicle exocytosis, the vesicles have been
divided into three different groups depending on their release competence following beta
cell stimulation: the readily released granules (RRP), the morphologically docked pool
(MDP) and the reserve pool (Bratanova-Tochkova et al., 2002). As its name implies, RRP
is the pool of granules that are immediately available to be released after stimulation. MDP
means that the granules have already docked on the plasma membrane and some of the
granules are already primed and others not. With regard to the reserve pools, they are larger
and more complex than RRP. Several reports indicated that some newly synthesized insulin
is stored in the reserve pools and is released preferentially. Capacitance studies showed that
in mouse beta cells, the total number of granules is estimated as13000, of which 0.3-0.7%
belong to the RRP group, 1-7% to the MDP, and the rest are comprised in the reserve pool.
That is, the total number of RRP granules ranges from 40 to 100, while the total number of
granules in the MDP and reserve pools is approximately 1,000 and 11,600, respectively
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(Bratanova-Tochkova et al., 2002). Insulin secretion is a biphasic process (Rorsman et al.,
2000). As RRP is responsible for the first phase of glucose stimulated insulin secretion, it is
obvious that the sustained second phase of glucose-stimulated release must involve
translocation of granules from reserve pools to the readily releasable pool or transformation
of morphologically docked granules to release competency before exocytosis.
Several hypotheses have been provided to explain the process of insulin vesicle exocytosis.
The soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor (SNARE)
hypothesis has attracted more attention (Lang, 1999). This hypothesis proposes the
formation of complex between the proteins located in the plasma membrane, syntaxin and
synaptosomal-associated protein 25 (SNAP-25) and the protein from the vesicle-associated
membrane protein 2 (VAMP-2)/synaptobrevin-2 (Lang and Jahn, 2008). At least 5 protein
super-families have been identified to be involved in this process, such as SNAREs,
Sec1/Munc18 (SM) proteins, Synaptotagmins, Rab proteins and Endocytic proteins.
Different proteins participate at different steps and play crucial roles. Loss of the fusion
between the membrane protein and vesicle completely blocked vesicle exocytosis.
Knocking down the protein “Munc18-1” decreased the second phase of insulin secretion
(Tomas et al., 2008). Rab plays a critical role in the formation, trafficking, and tethering of
vesicles to the target compartment in endocrine and nonendocrine cells. Rab27a deficient
mice showed decreased number of docked granules and insulin secretion (Kasai et al.,
2005). Besides these core proteins, the remodeling of F-actin also plays important roles in
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insulin exocytosis. F-actin negatively regulates exocytosis via binding and blocking
Syntaxin 4 accessibility (Jewell et al., 2008). But further studies indicate that metabolic
amplifying pathway increases both phases of insulin secretion and is independent on actin
microfilaments (Mourad et al., 2010).
The mechanism that underlies the biphasic nature of the insulin secretion process are still
poorly understood, but two well-established pathways have been characterized: the KATP-
dependent/triggering pathway and the KATP-independent/amplification pathway(Gilon et al.,
2002)
1.2.2 Inhibitors and stimulators of insulin secretion
It is well-accepted that insulin vesicle exocytosis needs some signal to switch from
“quiescence state” to “release state”. The signals that are implicated in stimulating insulin
secretion, named as stimulators (Fig 3), include mainly glucose, amino acids, FFA,
Glucagon, GLP-1, GIP, and acetylcholine. At the same time, the beta cells also employ
some signals to inhibit/ slow down insulin secretion, referred to as “inhibitors” (Fig 3).
Many inhibitors have been identified, in particular somatostatin, epinephrine and galanin.
In the following part, we will separately discuss the effect of each stimulator and inhibitor
on insulin secretion.
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Figure 3 Stimulators and inhitors of insulin secretion. Insulin vesicle exocytosis needs
some signal to switch between “quiescence state” and “release state”. As its name implied,
stimulators promote insulin secretion and inhibitors shut down insulin secretion. Several
stimulators, such as glucose, amino acids, fatty acids, glucagons, GLP-1, GIP and
acetylcholine have been identified and shown to enhance insulin secretion, while some
inhibitors, such as somatostatin, galanin, adrenalin and norepinephrine have been shown to
inhibit insulin secretion through different mechanisms as indicated in the text.
1.2.2.1 Glucose
Glucose is the most potent nutrient signal for the beta cell. The mechanism concerning
glucose as the potent signal is closely related to its metabolism inside the cells (Fig 4).
Following the increase in blood glucose concentration, the glucose sensing mechanisms
located in the beta cell drive glucose transporter 2 (GLUT2) to transport glucose into the
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cells, where it is oxidized via glycolysis and the TCA cycle to produce ATP. An increase in
the ratio ATP-to-ADP closes the ATP-sensitive K+ (K+ATP) channels, causing
depolarization of the plasma membrane, which in turn opens L-type voltage dependent Ca2+
channels. Along with Ca2+ efflux from ER, it would take part in priming the secretory
vesicles and also exocytosis. Additional mechanisms implicated in glucose signaling to
insulin secretion are discussed below.
Figure 4 Triggering and K+-ATP independent/ amplification pathways in beta cell
metabolic signaling. Multiple signals take part in inducing insulin secretion. After
glucose enters the cytosol through the Glut-2 transporter, it is converted into pyruvate.
Pyruvate enters mitochondrial and is oxidized in the tricarboxylate (TCA) cycle generating
NADH through electron transport chain that eventually results in ATP production. A rise in
cytosolic ATP causes the K+ channels of the plasma membrane to close with resultant
influx of Ca2+. Increased Ca2+ in the cytosol triggers the release of insulin from secretory
29
granules into the extracellular space. Metabolites derived from TCA cycle also act as
signaling molecules in the amplification pathways of insulin secretion.
1.2.2.2 FFA
At basal glucose concentration, FFA barely induces insulin secretion. But at high glucose
concentration, FFA potentiates glucose-stimulated insulin secretion. The mechanism
related to the effect of FFA can be explained by the "trident model" (Fig 5) (Nolan et al.,
2006b). The first two arms of this model related to the intracellular metabolism of FFA, and
the third arm implicates the FFA receptor (also known as GPR40) located in the plasma
membrane. The AMP-activated protein kinase/malonyl-CoA/long-chain acyl-CoA (LC-
CoA) signaling network is the first arm. At high glucose the level of malonyl-CoA
increases causing the switch in FFA metabolism from beta oxidation to esterification,
resulting in the availablitity of LC-CoA and acylglycerol (DAG, lysophosphatidic acid,
phosphatidic acid) intermediates for signaling purpose. The second arm is related to
glycerolipid/ free fatty acid (GL/FFA) cycling, which will be introduced in detail in the
next chapter. The third arm is related to signaling via the activation of the highly expressed
receptor GPR40, by medium to long chain FFA. GPR40 deficient mice have decreased
FFA potentiation of glucose-stimulated insulin secretion (Kebede et al., 2008).
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Figure 5 The trident model of beta cell lipid signaling. Three interdependent arms of
lipid signaling are proposed by which FFAs augment insulin secretion. First, glucose and
other nutrient secretagogues such as glutamine (Gln), Leucine (Leu), and α-ketoisocaproate
(KIC) contribute to anaplerosis, which allows cataplerotic efflux of citrate from
mitochondria. This results in malonyl-CoA (MALCoA) formation, inhibition of CPT-1
activity, and FA oxidation, and accumulation of LC-CoAs that stimulate insulin secretion
directly or by the formation of complex lipids such as DAG and various phospholipids (PL).
The second arm involves glucose-responsive TG/FFA cycling, due to the effects of glucose
to concomitantly promote FA esterification (provision of glycerol-3-phosphate [G-3-P] and
Mal-CoA inhibition of FA oxidation) and lipolysis processes. This allows, particularly in
the presence of exogenous FFAs, for the accumulation of cycle intermediates (LC-CoA,
DAG, PL, and FFA) that have signaling roles. Third, exogenous FFAs activate the cell
surface FA receptor, FFAR1/GPR40, which causes an increase in intracellular Ca2+. FFAs
formed from the hydrolysis of TG can cross the cell membrane and, together with
exogenous FFAs, activate FFAR1. Thus, the “trident pathways” of lipid amplification
intercommunicate and synergize to promote insulin secretion.
.
1.2.2.3 Amino acids
Individual amino acids alone do not induce insulin secretion at their physiological
concentrations. However, combination of some amino acids at high concentrations, such as
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L-alanine and glutamine and leucine (Newsholme et al., 2007), show strong stimulation of
insulin secretion. The mechanisms vary differently dependent on the type of amino acids.
L-Arginine, a cationically charged amino acid, can directly depolarize the plasma
membrane and causes insulin secretion; but this effect is dependent on the presence of
glucose. L-alanine has a more complex mechanism to stimulate insulin secretion. On one
hand, L-alanine can be co-transported with Na+, and thus can depolarize the plasma
membrane; on the other hand, L-alanine can be metabolized, to produce ATP, leading to
KATP channel closure. Both patways appear to promote Ca2+ influx and insulin secretion.
Leucine is known to activate glutamate dehydrogenase and thus strongly potentiates the
effect of L-glutamine in inducing insulin secretion via anaplerotic input (see below) into the
Krebs cycle (Yang et al., 2010b).
1.2.2.4 GLP-1 and GIP
Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are
two important gluco-incretins, and play crucial roles in inducing insulin secretion. GLP-1
and GIP contribute to more than 50% of the total post-prandial insulin secretion (Vilsboll
and Holst, 2004). GLP-1 is produced from enteroendocrine L- cells of the intestinal mucosa
and is released into the portal circulation in response to meal ingestion (Dalla Man et al.,
2010). GIP is produced from endocrine K-cells in the duodenum after ingestion of
carbohydrate and fat. The effect of GLP-1 in inducing insulin is not dependent on
intracellular fuel metabolism in the beta cell (Peyot et al., 2009a). Both GLP-1 and GIP
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exert their effects on insulin secretion through binding to their respective cell surface
receptors in beta cells and elevating the production of cAMP and Ca2+, which activate
downstream signaling patways that trigger insulin exocytosis.
1.2.2.5 Acetylcholine
Acetylcholine (Ach) is synthesized using the substrates acetyl-CoA and choline by choline
acetyltransferase in the cytoplasm. Then ACh is transported from the cytoplasm into the
vesicles by an antiporter (Su et al., 2007). Multiple evidences have shown that Ach released
by cholinergic nerve terminals that innevate the pancreas plays important roles in
stimulating insulin secretion, particularly during the “cephalic phase” of insulin secretion
that occurs prior to food intake when one sees a meal.
1.2.2.6 Somatostatin
Somatostatin, a growth-hormone-release inhibiting factor initially isolated from the
hypothalamus, inhibits insulin secretion. Somatostatin directly acts on beta cells, and
inhibit the initial and the late sustained phase of insulin secretion (Alberti et al., 1973). This
inhibitory effect is mediated by a G-protein receptor, which can decrease Ca2+ entry
through voltage-dependent Ca2+ channels. (Hsu et al., 1991). The somatostatin receptor
participates in the regulation of insulin secretion and glucose homeostasis. Somatostatin
receptor subtype 5 deficient mice show decreased blood glucose and plasma insulin and
increased leptin and glucagon concentrations (Strowski et al., 2003).
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1.2.2.7 Galanin
Galanin is a 29-amino-acid peptide, and is widely expressed in the peripheral and central
nervous systems. Galanin strongly inhibit insulin secretion in vitro and its in vivo
administration results in sustained hyperglycemia (McDonald et al., 1985). Further studies
have indicated that galanin inhibits insulin release, through a pathway involving a pertussis-
toxin-sensitive, guanine-nucleotide-binding regulatory protein, negatively coupled to
adenylate cyclase (Amiranoff et al., 1988). Galanin also inhibits exocytosis at a site distal
to and independent of the gating of K+ channels and the inhibition of adenylate cyclase
activity (Ullrich and Wollheim, 1989).
1.2.2.8 (Nor) epinephrine
Epinephrine in the blood and norepinephrine released by adrenergic nerve terminals play a
role in regulating insulin secretion and action during stress and exercise. Epinephrine,
acting primarily through a ¦Â-adrenergic receptor, markedly reduce tissue insulin sensitivity
and this effect results from both peripheral and hepatic resistance to the action of insulin
(Deibert and DeFronzo, 1980) These catecholamines via α-adrenergic receptors reduce
insulin secretion and are particularly important to prevent hypoglycemia when muscle
contraction promotes glucose uptake by tissues, and when enhanced whole body glucose
oxidation is required (Gerich et al., 1991).
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1.2.3 Metabolic signals promoting insulin secretion
Nutrient secretagogues induce activation of beta cell metabolism and ATP production,
which precedes the rise in Ca2+ and secretion. The availability of substrates and their
metabolism causes the production of metabolic coupling factors (MCF) leading to the
insulin release (Fig 6). The initial metabolism of fuels in the beta cells appears to be
governed by a “push” (substrate availability) than a “pull” (Ca2+ influx driving
mitochondrial metabolism), unlike other tissues (Peyot et al., 2009a).
Figure 6 Candidate coupling factors in fuel-induced insulin secretion. Nutrient
secretagogues induce activation of beta cell metabolism and ATP production. The
availability of substrates and their metabolism causes the production of metabolic coupling
factors (MCF) leading to the release of insulin. Several MCF, including ATP, ADP, GTP,
Malonyl-CoA, DAG, citrate, ROS, NADPH have been proposed to play key role in
promoting insulin secretion.
1.2.3.1 Mitochondrial signals: anaplerosis, cataplerosis and pyruvate cycling
35
Cataplerosis and anaplerosis are processes that represent the efflux of Krebs’ cycle
intermediates from mitochondria into the cytosol, and their replenishment, respectively
(Farfari et al., 2000; Schuit et al., 1997). Both processes are quantitatively similar because
the Krebs’ cycle is not a sink for glucose carbons (Brun et al., 1996; Schuit et al., 1997). In
the beta cells, anaplerosis and cataplerosis pathways are thought to provide the carbon
precursors (eg citrate) of MCF for insulin secretion (Fig 7). Cytosolic citrate increases at
high glucose concentration in the beta cell, and it has been shown that pyruvate cycling
allows for high glycolytic flux via NADH reoxidation and the production of two MCF,
malonyl-CoA (MalCoA) and NADPH (Guay et al., 2007). Altered flux through anaplerosis,
in response to glucose correlates with MCF production and insulin secretion (Jensen et al.,
2008). The expression of pyruvate caboxylase (PC), malic enzyme (ME) and ATP-citrate
lyase (ACL), enzymes of the pyruvate/citrate cycle is defective in islets from humans with
T2D (Jitrapakdee et al., 2010). PC expression is reduced in islets of the diabetic GK and
ZDF rats (MacDonald et al., 1996). RNAi-knockdown of PC (Hasan et al., 2008), ME
(Guay et al., 2007; Ronnebaum et al., 2008) and ACL (Guay et al., 2007) curtailed GSIS.
Although some studies have questioned the role of ACL and ME in beta cell signaling
(Ronnebaum et al., 2008), there is a general consensus that pyruvete cycling processes are
implicated in the regulation of beta cell fuel signaling. Thus, inhibition of one cycling
process may in some studies be compensated by enhanced flux through another pyruvate
cycling pathway.
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Figure 7 pyruvate cycling and insulin secretion. Pyruvate-derived from glucose
metabolism enters in the tricarboxylic acid cycle via its carboxylation by PC, producing
oxaloacetate (OAA). This anaplerotic process leads to the formation and accumulation of
citrate within the mitochondria. At increasing levels, mitochondrial citrate is exported into
the cytoplasm in exchange with malate. Once in the cytosol, citrate is cleaved by ACL,
producing pyruvate, leading to the production of NADPH. Pyruvate re-enters the
mitochondria via the pyruvate transporter. The pyruvate/citrate cycling together with
glucose-derived pyruvate leads to the net synthesis of malonyl-CoA, NAD+, NADPH, and
indirectly ATP, which increased insulin secretion.
1.2.3.2 NADPH, Adenine and Guanine Nucleotides and Glutamate
Ample evidence implicates cytosolic NADPH as a MCF. GSIS positively correlates with
the NADPH/NADP ratio and NADPH directly induces exocytosis in single beta cells.
Recent studies (Reinbothe et al., 2009) indicate that NADPH acts via glutaredoxin-1 that
may control exocytotic effectors and/ or voltage K+ channels Kv 2.1 to promote the rise of
37
Ca2+. Several studies demonstrated that ATP and ADP act as MCF in the beta cell. It has
also been suggested that mitochondrial GTP positively regulates GSIS via mitochondrial
Ca2+ handling (Kibbey et al., 2007). Glucose-derived glutamate, via the glutamate
dehydrogenase reaction, was proposed to act as MCF. Thus, activating mutations in GDH
are associated with hyperinsulinemia (Kranendijk et al., 2010). However, the view that
glutamate as a MCF has been challenged (Malaisse et al., 1979), and the evidence indicates
that anaplerotic oxidative deamination of glutamate via GDH, producing alpha-
ketoglutarate in the Krebs cycle (Agarwal et al., 2006), is implicated in this type of
hypersulinemia.
1.2.3.3 Lipid metabolism dependent amplification of beta cell metabolic signaling
Glucose metabolism leads to a rise in MalCoA, which inhibits carnitine
palmitoyltransferase-1 (CPT-1) and blocks beta-oxidation and thus causes a fuel shift in
beta cells from fatty acid to glucose utilization (figure 8). Overwhelming support for the
MalCoA/CPT-1 interaction and fatty acyl-CoA, or their derivations such as diacylglycerol
(DAG), in beta cell fuel stimulation was provided by our lab and others. Thus,
overexpression of MalCoA decarboxylase (MCD) in the cytosol or a MalCoA-insenstive
CPT-1 mutant in the beta cell curtailed GSIS (Roduit et al., 2004). Nutrient inhibition of
fatty acid oxidation is accompanied by elevated glycerolipid (GL) formation and significant
increases in the total mass of DAG, triacylglycerol (TG) and phosphatidic acid (PA) were
shown to occur in glucose-stimulated beta cells. Inhibition of beta oxidation by MalCoA
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leads to a rise in cytosolic FACoA, and, as far as signaling is concerned, FACoA, FFA
themselves and complex lipids (DAG, lysophophatidic acid and PA) are potential MCF, as
these compounds directly influence signaling pathways and secretion. MalCoA/lipid
signaling is important not only in beta cells as we initially proposed, but also in the control
of insulin action, appetite and body weight.
Figure 8 Interactions between glucose and fatty acid metabolism in nutrient-secretion
coupling. This model illustrates the synergistic interaction between glucose and FA
metabolism and the generation of lipid signaling molecules that augment GSIS. Glucose
gives rise to pyruvate, which, when channeled through pyruvate dehydrogenase (PDH),
contributes to induction of insulin secretion via ATP production and the KATP-dependent
triggering pathway. Pyruvate alternatively can be channeled via pyruvate carboxylase (PC)
into the anaplerosis/cataplerosis pathway, which contributes to increases in cytosolic
oxaloacetate (OAA) and citrate. Glucose increases malonyl-CoA (Mal-CoA), which blocks
FA oxidation by inhibiting CPT-1. Inhibition of FA oxidation allows LC-CoA esters to
accumulate in the cytosol. LC-CoAs are formed from FFAs supplied externally or produced
by the lipolysis of endogenous TG. LC-CoAs can be esterified with glycerol-3-phosphate
(Glyc-3-P) to form complex lipids such as TG, DAG, and phospholipids (PL). Glucose also
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activates lipolysis, which favors TG/FFA cycling from endogenous lipids. Exogenous
FFAs (FFAExog contribute by amplifying the levels of cycle intermediates (LC-CoAs, TG,
DAG, PL, and intracellular FFAs [FFAIC themselves), all of which may be implicated in
lipid signaling effector pathways. ¦Â-oxid, ¦Â-oxidation; [Ca++]IC, intracellular calcium.
1.3 Glycerolipid/free fatty acid cycle (GL/FFA cycle)
GL/FFA cycle, previously named as triacylglycerol/ free fatty acid cycle (TG/FFA cycle),
did not draw great attention since its description in 1965. With the rapidly increasing
knowledge of the mechanisms of obesity and diabetes, it is gradually becoming evident that
this cycle located at the heart of the metabolic network, tightly linking glucose and FFA
metabolism together, with important roles in churning out a plethora of signaling molecules
controlling numerous biological processes (Prentki and Madiraju, 2008).
1.3.1 The process of GL/FFA cycle and related enzymes
GL/FFA cycle (figure 9) is a continuous active process and shown to exist in almost every
cell type. The biological process of this cycle encompasses esterification of FFA onto a
glycerol backbone to synthesize glycerolipids followed by their hydrolysis with the release
of the FFA that can be re-esterified. The full cycle contains two continuous steps-
lipogenesis and lipolysis. Lipogenesis starts from glycerol-3-phosphate generated from
glycolysis or gluconeogenesis and fatty acid-CoA from fatty acid synthesis or exogenous
fatty acid, to synthesize lysophosphatidic acid (LPA) in the presence of glycerolphosphate
acyltransferace (GPAT). LPA can be further esterified into phosphatidic acid (PA), which
is converted into diacylglycerol (DAG) and triacylglycerol (TG), the main energy form
stored in the lipid droplets. LPA, PA and DAG arising from GL/FFA cycle can also be
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incorporated into phospholipids. Following lipogenesis, the final product TG and some
phospholipids enter the “lipolysis” process to produce DAG, monoacylglycerol (MAG),
and glycerol as well as free fatty acids, released at each step. Relative to the full cycle, in
some conditions to produce certain special signaling molecule, the cells may hold several
short product/ substrate cycles, such as from PA to DAG, which will converted to PA
instead of incorporating into TG (figure 9).
Figure 9 Enzymes and intermediates of the triacylglycerol/free fatty acid cycle. Fatty
acyl-CoA (FACoA) is formed by long-chain acyl-CoA synthase (ACSL) from free fatty
acids (FFA) supplied externally or produced by the hydrolysis of triacylglycerol (TG),
diacylglycerol (DAG) and monoacylglycerol (MAG). The accumulating FACoA is
partitioned into the formation of complex lipids through the condensation with glucose-
derived glycerol-3-PO4 (Gly3P) by glycerol-3- phosphate acyltransferase (GPAT) to form
lysophosphatidic acid (LPA). LPA is further converted by acyl glycerol-3-phosphate
acyltransferase (AGPAT) to phosphatidic acid (PA), which eventually gives rise to DAG
by the action of phosphatidic acid phosphatase (PAP), or phospholipids (PL). DAG thus
formed is acylated by diglyceride acyltransferase (DGAT) to form TG. DAG derived from
TG by adipose triglyceride lipase (ATGL) and/or hormone sensitive lipase (HSL), is
hydrolyzed to 2-MAG by HSL. 2-MAG is hydrolyzed by MAG lipase (MGL) to FFA and
glycerol, which is secreted out of the cell. In some cells the released glycerol is recycled
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back into TG/FFA cycling by conversion to Gly-3-P by glycerokinase. ¦Â-ox, oxidation.
It is now well-accepted that the GL/FFA cycle is under stringent control via separate
enzymes responsible for forward and backward reactions. The rate-limiting step in this
cycle lies in the initial step involved in glycerol-3-phosphate and fatty acid-CoA to produce
LPA. So the enzyme glycerol-3-phophate transferate (GPAT) involved in this step is of
high importance. Till today, four enzymes have been cloned and identified, viz., GPAT1 to
GPAT4. GPAT1 and GPAT2 are localized in the mitochondria, while GPAT3 and 4 are in
the ER. Mitochondrial GPAT1 has been characterized more thoroughly than the other
isoforms. GPAT1 deficient mice displayed markedly lower hepatic TG and DAG
concentration, and were protected from hepatic steatosis (Xu et al., 2006) and hepatic
insulin resistance possibly due to a lower DAG-mediated PKC activation. Further study
using the metabolomics analysis showed that several metabolites, including palmitate, 1-
mono-16:0-glycerol, 1,2-di-16:0-glycerol were decreased, and other metabolites involved
in carbohydrate metabolism were increased in the knock out mice, which may provide
important clues to explain high insulin sensitivity in this kind of mice. The second enzyme
involved in this cycle is 1-acyl-sn-glycerol-3-phosphate acyltransferase, also named as
lysophophatidic acid acyltransferase (LPAAT), catalyzing the reaction from LPA to PA.
Several isoforms of LPAAT have been identified, of which only alpha and beta show high
activity. Agpat2?á/?b mice develop severe lipodystrophy affecting both white and brown
adipose tissue, extreme insulin resistance, diabetes, and hepatic steatosis associated with
high expression of lipogenic genes and high rates of de novo fatty acid biosynthesis. PA
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phosphatase (PAP) is responsible for converting PA to DAG. In mammals, two types of
PAP (PAP1 and PAP2) have been recognized. PAP-1 is found mainly in the ER and
believed to be involved in the synthesis of TG and PL. PAP-2 is located near the plasma
membrane and may be producing DAG form PA released from membrane.
The next important enzyme involved in acylating DAG to TG is diacylglycerol
acyltransferase (DGAT), with important roles in regulating energy storage and metabolism.
Two type of DGAT (DGAT1 and DGAT2) exist in the mammals. DGAT1 has been
reported to be highly expressed in skeletal muscle, intestine as well as other tissues,
whereas DGAT2 is mostly expressed in the adipocytes and liver. Overexpression of
DGAT1 in rat islets has been shown to increase palmitate incorporation into TG resulting
in a modest accumulation in TG content and decreased glucose-stimulated insulin secretion,
which may be due to “glucolipotoxicity”. DGAT-1 knock out mice were shown to have
increased insulin sensitivity and enhanced glucose tolerance, and protected from diet-
induced obesity (Yamaguchi et al., 2008); DGAT2 also plays a fundamental role in
mammalian triglyceride synthesis and is required for survival based on the fact that
DGAT2-deficient (Dgat2-/-) mice are lipopenic and die soon after birth, apparently from
profound reductions in substrates for energy metabolism and from impaired permeability
barrier function in the skin. Also in these KO mice, DGAT1 was unable to compensate for
the absence of DGAT2, supporting the hypothesis that the two enzymes play fundamentally
different roles in mammalian triglyceride metabolism.
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The process of lipolysis is also highly dependent on several important enzymes, depending
on different reactions. The first well-known TG lipase is adipose TG lipase (ATGL; also
named desnutrin and patatin-like domain containing phospholipase A2, PNPLA2 or
PLA2¦Æ), which is proved to function in catalyzing TG to produce 2,3-DAG instead of 1,2-
DAG. It is becoming evident that ATGL prefers to hydrolyse TG at sn-1 position. Hormone
sensitive lipase (HSL) was shown to exhibit activities to hydrolyse TG, DAG and MAG in
vitro, but its main role in vivo was revealed to hydrolyse DAG to MAG better than MAG to
glycerol. Other DAG lipases, such as sn1-DAG lipase, have been identified, but their
relative contribution for DAG hydrolysis is still unclear. sn-1 DAG lipases show high
activity in brain and pancreatic beta cells compared to other tissues. This enzyme shows
remarkable specificity to DAG containing arachidonic acid (AA) at position 2 to release 2-
arachidonic glycerol (2-AG), which is an important signaling molecule in stimulating CB-1
and CB-2 receptors. The MAG produced by DAG lipase is further hydrolysed by MAG
lipase. Several enzymes have been proven to show MAG lipase activity in vitro. Of special
interest, MAG lipase (MAGL), ABHD6 and ABHD12 contribute to almost the whole
MAG hydrolytic activity in brain (Blankman et al., 2007). It is well-known that all the
MAG lipases are capable of hydrolyzing both 1-MAG and 2-MAG. We will discuss the
MAG lipases in detail in the following part.
1.3.2 MAG lipases
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The first classical MAG hydrolyzing enzyme identified was MAG lipase, which was for a
long time recognized as the main MAG lipase in all cell types (Farooqui et al., 1984). MAG
lipase has been reported to increase several fold in some cancer cells during cancer
progression. Further studies indicated that MAG lipase controls a MAG-FFA network to
regulate cancer cell migration and progression. Knockdown of this protein could inhibit
cancer cell migration, which could be reversed by adding exogenous stearic acid and
palmitic acid, independent of CB1 and CB2 pathway (Nomura et al., 2010). In 2007,
another two enzymes ABHD6 and ABHD12 were identified using activity based protein
profiling methods in the brain tissue (Blankman et al., 2007), and these two enzymes were
shown to contribute to 15% of the total MAG lipase activity in the brain, as classical MAG
lipase is responsible for the remaining 85%. Recent studies have shown that ABHD6 is
highly expressed in several tumor cell lines, such as breast cancer cell line MCF7, but the
significance of this high expression is not clear (Max et al., 2009). Another report
demonstrated that inhibition of ABHD6 in brain produced the cannabnoid effect via
accumulation of 2-AG, indicating the important roles of ABHD6 in regulating cell function
(Marrs et al., 2010). Even though it has been demonstrated that efficient lipolysis takes
place in beta cells in response to glucose stimulation, resulting in the production and release
of both glycerol and FFA, the terminal lipase involved in MAG hydrolysis has not been
characterized. The relative contributions of classical MAG lipase (inhibited specifically by
JZL184), ABHD6 (inhibited specifically by WWL70) and ABHD12 to MAG hydrolysis in
beta cells are yet to be worked out.
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1.3.3 Functions of GL/FFA cycle
As indicated above, GL/FFA cycle consists of multiple steps, catalyzed by separate
enzymes also in the forward and backward directions. Such a complex enzyme system
offers several “regulating points” to better and more conveniently control this cycle, in
order to meet the diverse needs of signaling metabolite supply for the biological functions
of the cell. Any disturbance of this cycle leads to a wide range of pathophysiological
phenomena, including type-2 diabetes and cancer (figure 10).
Figure 10. Biological processes regulated by GL/FFA cycling. Operation of GL/FFA
cycling generates various metabolites and signals involved in the control of multiple
biological processes. The figure illustrates established and candidates processes as well as
those clearly emerging from recent studies. ER, endoplasmic reticulum; HS, heat shock; EC,
endocannabinoid (Prentki and Madiraju, 2008).
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The GL/FFA cycle is capable of producing a plethora of signaling molecules controlling
numerous biological processes. Their roles could be divided into three categories:
established roles, emerging roles as well as candidate roles. The established role was
related to energy homeostasis and thermogenesis. In mammals, maintenance of body
temperature is at least in part, if not largely dependent on lipolysis, an integral part of
GL/FFA cycle. FFA produced from lipolysis can activate mitochondrial uncoupling
proteins (UCPs), which act to uncouple the respiration from oxidative phophorylation and
help in dissipating the respiratory energy as heat. The decreased ability to mount adequate
thermogenic response by enhancing lipolysis may be responsible for the reduced tolerance
to cold of ob/ob mice, ATGL-KO mice and Zucker fatty rats.
Besides the established roles, there are many emerging roles of GL/FFA cycle, which
encompasse a whole range of regulatory functions and include detoxification of fuel
oversupply, regulation cell survival and proliferation, regulation of gene expression as well
as insulin secretion (Prentki and Madiraju, 2008).
It has been hypothesized (Nolan and Prentki, 2008; Prentki and Madiraju, 2008)(figure 11)
that GL/FFA cycle allows for fuel detoxification because it directs the glucose carbon to
glycerol, which leaves beta cell that express little glycerol kinase. Furthermore, FFA
released from lipolysis are also transported out of the cells or transported in to
mitochondria for beta oxidation. As GL/FFA cycle is a high energy-consuming pathway,
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several ATP molecules are hydrolyzed (7 per cycle) and the energy is released in the form
of heat during one full cycle. Some steps in the cycle have been shown to involve in ATP
usage, such as FFA conversion into fatty acid-CoA and LPA synthesis. The released heat is
beneficial to maintain mammal body temperature as well as for fuel detoxification.
Figure 11 GL/FFA cycling and nutrient gluco-lipo-detoxification. Glucose metabolism
via the GL/FA cycle provides an alternative pathway to mitochondrial oxidation for
glucose metabolism in the ¦Â-cell that also produces important coupling factors for secretion.
This pathway can also act to detoxify excess nutrients. Glucose metabolised via glycerol-3-
phosphate (Gly3P) in the GL/FA cycle has its carbons released from the cell in the glycerol
form (GL) and not oxidized, termed gluco-detoxification (Glc Detox). Activation of the
lipolysis arm prevents accumulation of complex GL and steatosis. ¦Â-oxidation (¦Â-ox) of
fatty acid to CO2 and acid soluble products (ASP) is supported by maintenance of long
chain acyl-CoA (LC-CoA) substrate levels and the fact that AMP produced by FFA
activation promotes AMP-Kinase (AMPK) activation. AMPK upregulates ¦Â-oxidation in
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many cell types, including the ¦Â-cell, allowing for lipo-detoxification. The cycle also
utilizes ATP, which dissipates the mitochondrial membrane potential, lessening the
likelihood of cellular damage by mitochondrial dysfunction (Mit dysf) and reactive oxygen
species (ROS) production. Diversion of glucose metabolism via GL/FA cycling is also
likely to reduce effects of glucose toxicity on endoplasmic reticulum stress (ERs) and cell
damage (Nolan and Prentki, 2008).
Regulation of gene expression is also one of the most important roles of GL/FFA cycle.
Some metabolites, such as DAG are produced during cycling could directly or indirectly
activate or elevate the level of hypoxia inducible factor 1alpha (HIF-1alpha), a vital
transcription factor that regulates the expression of various glycolytic enzymes, vascular
endothelial growth factor (VEGF) and also favors cell survival. Also protein lysine
acetylation has emerged as a key posttranslational modification in celluar regulation, and
some reports showed lysine acetylation is a prevalent modification in enzymes that catalyze
intermediate metabolism according to cellular nutrition conditions. GL/FFA cycle is a very
active metabolic pathway, which continuously uses NADH and regenerates NAD, which is
a substrate for the protein deacetyltion enzymes, sirtuins, which regulate a wide range of
cellular functions including gene expression. Thus it is possible that GL/FFA cycle controls
gene expression by regulating sirtuin activity and protein lysine deacetylation. Also,
because of the ability of GL/FFA cycle to activate sirtuins, which are well known for their
involvement in promoting longevity, the possibility that GL/FFA cycle indirectly
contributes to longevity exists.
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GL/FFA cycle may participate in the regulation of cell survival and proliferation through
TG deposit in non-adipose cells. High concentration of FFA in combination with high
concentration of glucose is really toxic to non-adipose cells, such as beta cells, which could
interfere with many cellular processes, in particular mitochondrial function and energy
homeostasis. Several reports have shown that TG accumulation in non-adipose cells could
be regarded as a defective mechanism against acute FFA toxicity. TG build-up, together
with high active GL/FFA cycle could protect the cells as long as the cells retain the ability
to hydrolyse TG to maintain the amount of TG in a reasonable extent. The roles related to
insulin secretion will be discussed in detail in next chapter.
1.3.4 Regulation of insulin secretion by the GL/FFA in beta cells
The significance of GL/FFA cycling for insulin secretion became evident from studies
showing curtailed GSIS in rat islets upon lipolysis inhibition by the pan-lipase inhibitors
3,5-dimethylpyrazole (Masiello et al., 2002) and orlistat (Mulder et al., 2004). In rat and
mouse islets, the lipase activity is proportional to insulin secretion. ATGL and HSL have
been implicated in the process of insulin secretion. Knockdown of these two proteins using
siRNA has been shown to decrease insulin secretion in cell lines. Furthermore, mice
deficient in ATGL have shown decreased insulin secretion in vivo and ex vivo (Peyot et al.,
2009b). Studies with the whole body HSL-deficient mice showed inconsistent results based
on genetic background of the KO mice. While some reports showed no influence on insulin
secretion in HSL-KO mice other reports showed clear reduction in insulin secretion
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especially in fasted male mice (Mulder et al., 2003; Peyot et al., 2004). This discrepancy
was resolved in the beta cell-specific HSL-knockout mice, which showed significantly
reduced insulin secretion (Fex et al., 2009). Although the lipases ATGL and HSL are
implicated in insulin secretion, little is known about the role of MAGL, ABHD6 and
ABHD12 in insulin secretion. Definition of their roles in the beta cell is of interest because
these enzymes are indispensable for completing lipolysis, and we hypothesized that they
may also have an important role in regulating insulin secretion.
The other arm of the GL/FFA cycle (lipogenesis) may also take part in insulin secretion.
Some studies have shown that rapid lipogenesis and lipid remodeling from secretagogue
carbons support insulin secretion in INS832/13 cell line (MacDonald et al., 2008). Glucose
carbon rapidly incorporates into different classes of lipids in the beta cell (Prentki and
Madiraju, 2008), indicating the high active of lipogenesis, important part of GL/FFA cycle.
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Figure 12 Model illustrating the role of the free fatty acids (FFA) and the
glycerolipid/fatty acid (GL/FA) cycle in the regulation of insulin secretion as a
function of the nutritional state. During fasting (a), the ¦Â-cell triggering pathway of
glucose signaling is inactive, ensuring that insulin secretion remains low even though FFA
are elevated under this nutritional condition. Furthermore, FFA are preferentially oxidized
rather than cycled, as the level of glucose-derived malonyl-CoA (MalCoA) is low. FFA
signaling via GPR40 is insufficient to promote insulin secretion when the triggering
pathway is inactive. After a meal (b), increased ¦Â-cell glucose metabolism promotes insulin
secretion by activating both the triggering and GL/FA cycle amplification pathways.
Triggering occurs as a result of glucose oxidation and the K+ATP channel dependent
pathway. Glucose promotes GL/FA cycling by increasing MalCoA which blocks ¦Â-
oxidation which allows long chain acyl-CoA (LC-CoA) availability for the cycle, providing
glycerol-3-phosphate (Gly3P) for synthesis of GL such as lysophosphatidic acid,
diacylglycerols and triacylglycerols, and activating lipolysis. In the presence of these
glucose-derived signals, direct signaling of FFA via GPR40 is now able to amplify
secretion. The ‘off signal’ for the GL/FA cycle amplification pathway is ¦Â-oxidation, since
it depletes lipid metabolites from the cycle. The ‘on signal’ is the cycling itself that is
promoted by elevated glucose (Nolan and Prentki, 2008).
1.4 TRP channels
Transient Receptor Potential (TRP) channels constitute a large and diverse family of
proteins, which are classified into at least three main subfamilies of closely related channels
called canonical (TRPC), vanilloid (TRPV) and melastatin-related (TRPM) channels, as
well as four additional groups of more distantly related TRP subfamilies named TRPA
(ankyrin), TRPP, TRPML and TRPN) (Venkatachalam and Montell, 2007). TRP channels
are present almost in every organ. They are higly expressed in brain but also located in the
heart, heart, kidney, testis, lung, liver, spleen, pancreases, ovaries, intestine, prostate,
placenta, uterus, and vascular tissues. They are also reported to be widely expressed in
different cell types, such as neural cells, muscle cells and endothelial cells. TRP channels
show very similar structures, conserved from one to another species (Moiseenkova-Bell
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and Wensel, 2009). The TRP channel proteins possess six transmembrane domains, which
anchor the channel to the lipid bilayer of the membrane. Compared to the classical voltage-
gated channels, TRP channels do not have a voltage sensor domain, and are regarded as a
non-selective cation channels. All the TRP channels show varying degrees of permeability
to cations; of special interest, some of the TRP channels are highly permeable to calcium
(Birnbaumer, 2009).
Different approaches, such as over-expression of dominant-negative variants, antisense
oligonucleotides, RNAi and targeted deletion of the gene using homologous recombination
both in the cells and in the mice, have been widely used to uncover the roles of TRP
channel proteins. It has been widely accepted that TRP families play important roles in
regulating cell functions, such as thermosensation, pheromone reception, magnesium
homeostasis as well as regulation of vascular tone. Loss of activity of TRP channels have
been implicated in severe human diseases, including some cancers (Venkatachalam and
Montell, 2007).
The activation of TRP channels can occur in several different ways: in some cases, they can
be activated by background currents, whereas in others, activation needs some special
stimulators, such as endogenous agonists. In either case, a functional unit of TRP channel
requires tetrameric assembly of homomeric or heteromeric TRP peptides.
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1.4.1 TRP channels identified in beta cells
As a non-selective cation channels, some TRP channels may be permeable to calcium and
then regulate beta cell function. Till now, three subfamilies (TRPC, TRPM and TRPV)
have been identified in beta cells.
1.4.1.1 TRPC subfamily
The subfamily of TRPC consists of at least seven subtypes: from TRPC1 to TRPC7. Three
subtypes- TRPC1, TRPC4 and TRPV6 have been identified in the beta cell. TRPC1
channel was the first cloned TRP channel in mammals based on the high sequence
similarities to Drosphila melaogaster, and it is also the first TRP protein identified in the
beta cells. TRPC1 is highly expressed in the brain, heart, testes, ovary, bovine aortic
endothelial cells, and salivary glands. (Song and Yuan, 2010). TRPC1 was reported to form
functionally distinct heteromers with its close relatives TRPC3 and TRPC5 (Clapham et al.,
2001). As an assumed store-operated channel, it is not very clear that the activation of
TRPC1 is mediated by release of stored calcium or through phospholipase c (PLC)
dependent pathways.
The functions of TRPC1 in the beta cells have not yet been reported. TRPC4 is structurally
similar to TRPC1, and it is reported to be highly expressed in the brain and adrenal grand.
In the beta cells, TRPC4 transcripts are easily detectable in mouse islets using RT-PCR.
TRPC4 is activated by G-protein families and receptor tyrosine kinases. The role of TRPC4
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in beta cells is not known because TRPC4-deficient mice did not show any difference in
glucose tolerance (Freichel et al., 2004). TRPC6 is sensitive to DAG in a manner that is
independent of protein kinase C (PKC) activity. It was postulated that it form heteromers
with TRPC3 and TRPC7. TRPC6-deficient mice have been shown to have 3 fold increase
in the mRNA of TRPC3, indicating a functional redundancy (Dietrich et al., 2005). The
mRNA level of TRPC6 in the beta cells is very low and its role in this cell type is not
known.
1.4.1.2 TRPM channels
The TRPM subfamily consists of at least eight subtypes: TRPM1 to TRPM8. TRPM2,
TRPM3 and TRPM5 have been identified in the beta cells (REF). TRPM2, also named
LPRPC2, binds ADP ribose (ADPR) and nicotinamide dinucleotide (NAD). TRPM2
activity is modulated by variations in the cellular redox state (Togashi et al., 2006). TRPM2
is thought to regulate cell death induced by changes of the cellular redox state. In the beta
cells, TRPM2 has been detected in the mouse, rat and human islets, and activation of
TRPM2, by the change of the temperature, could strongly stimulate insulin secretion
(Uchida et al., 2010). TRPM3 was also identified and cloned from beta cells, and it was
proposed to function as ionotropic steroid receptors in pancreatic ¦Âcells (Wagner et al.,
2008).. TRPM3 channels are highly permeable and conductive for Zn2+. Of special
importance, TRPM3 channels mediate Zn2+ uptake in pancreatic ¦Â-cells independently of
VGCCs and the uptake could take place even in the very low concentration of Zn2+ outside
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the cells, and consequence, TRPM3 constitutes a regulated entry for Zn2+ ions in beta cells
(Wagner et al., 2010).
TRPM5 seems to have a wide range of tissue distribution, including beta cells. This
channel could mediate calcium-activated, non-selective cationic currents, and therefore,
may regulate many biological processes inside the cells. Using TRPM5-deficient mice, this
channel has been shown to be essential for sweet, umami, and bitter taste reception directly
or indirectly through PLC pathway (Riera et al., 2009; Sugita, 2006). In the beta cells,
TRPM5 may play an important role in regulating insulin secretion, but till now, there is still
no direct evidence to support this hypothesis.
1.4.1.3 TRPV subfamily
The subfamily of TRPV consists of at least six subtypes: from TRPV1 to TRPV6. And in
the beta cells, TRPV1 and TRPV2 are already identified. TRPV1 is highly expressed in
dorsal root ganglia (DRG) as well as neurons. As a non-selective cation channel, it has been
shown to cause calcium influx in different cell types, as a result, it could regulate many
processes, such as relieve of pain. Activation of TRPV1 by dietary capsaicin improves
endothelium-dependent vasorelaxation, and more importantly, it prevents hypertension
(Yang et al., 2010a). TRPV2 also has a wide tissue distribution, and mainly in the neurons,
neuroendocrine cells in the gastrointestinal tract and blood cells such as macrophages
(Vennekens et al., 2008). As a heat-sensitive channel, TRPV2 channel could be activated
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by a noxious temperature (>52°C) - the physiological significance of which is the possible
to link with nociception. Besides heat, it also could be activated by growth factors and other
ligands. One characteristic of TRPV2 channel protein is that it could translocate from
cytoplasm to plasma membrane after different stimulation, such as IGF-1. Because of its
identification in beta cells, such as mouse islets, special interest has been paid to the effect
of insulin secretion and TRPV2. Now it is clear that TRPV2 functions as an insulin-
mediated regulator of calcium entry (Hisanaga et al., 2009). Further studies implicated
TRPV2 in the regulation of the first phase of insulin secretion (Aoyagi et al., 2010).
1.4.2 TRPV1 and beta cell function
TRPV1 has been identified in the beta cells, and also has been shown to play a role in
regulating beta cell function, such as insulin secretion (Akiba et al., 2004). Many stimuli
have been shown to activate TRPV1, which included heat (>43°C) and capsaicin (Caterina
et al., 1997), protons (<pH 6) (Latorre et al., 2007) and cations (Ahern et al., 2005); some
lipids and their derivatives, including n-arachidonoyldopamine (NADA), n-oleoyldopamine,
anandamide, oleoylethanolamide and other N-acylethanolamines (and lipoxygenase
derivatives. And more recently MAG was shown to activate TRPV1 and cause calcium
influx in HEK cell line (Iwasaki et al., 2008). We think this finding is highly important,
because MAG is a common metabolite from the sequential hydrolysis TG. MAG could
activate TRPV1, which has been shown to play important role in calcium influx causing
insulin secretion.
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TRPV1 has been detected using western blotting in INS-1 cell line as well as rat islets and
its agonists could induce insulin secretion, even in the basal condition (1mM glucose)
(Akiba et al., 2004). Systemic use of capsaicin could increase glucose tolerance in the
Zucker fatty rat (Gram et al., 2007). TRPV-1 deficient mice have been generated and
proved to be resistant to obesity after high fat feeding (Motter and Ahern, 2008). And
TRPV-1 has been shown not only located inside the beta cells, and also in the nerve fibres
in the islets (Razavi et al., 2006).
1.5 Hypothesis
Glycerolipid/ free fatty acid cycling with its lipolysis and lipogenesis segments, contributes
to the lipid-amplification pathways of promoting GSIS in -cells. GL/FFA cycle is
suggested to produce different lipid signaling molecules that enhance insulin secretion
(Prentki and Madiraju, 2008). The significance of lipolysis in this signal molecule
production has been well-documented by the studies showing curtailed GSIS in -cells
upon lipolysis inhibition by the pan-lipase inhibitors orlistat (Winzell et al., 2006) and 3,5-
dimethylpyrazole (Masiello et al., 2002). Orlistat was also shown to antagonize palmitate-
augmented GSIS (Nolan et al., 2006b). However, the precise lipid molecule(s) or the
enzyme involved has not been identified. Even though the role of HSL, which conducts
DAG hydrolysis in the GL/FFA cycle, in insulin secretion has been debated (Mulder et al.,
2003), Prentki group provided convincing evidence for the importance of HSL (Peyot et al.,
2004; Roduit et al., 2001) in the regulation of GSIS both in vivo and in vitro and this has
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been confirmed recently by others (Fex et al., 2009) using -cell specific HSL-knockout
mice. Specific inhibition of another DAG hydrolyzing enzyme, sn1-DAG lipase, by
RHC80267 in -cells was also found to reduce GSIS (Guenifi et al., 2001; Konrad et al.,
1994). Besides DAG hydrolysis, lipolysis of triglycerides by ATGL is also shown to be
important by a study from Prentki lab, in fuel and non-fuel stimulated insulin secretion
(Peyot et al., 2009b). It was proposed that DAG is a potential signaling molecule that is
involved in the lipid-amplification of GSIS, as DAG can activate munc-13, which is
essential for insulin exocytosis and also PKC enzymes that are important for GSIS.
Inasmuch as either the lack or inhibition of ATGL, HSL or sn1-DAG lipase in -cells,
leads to reduced insulin secretion and because orlistat also inhibits palmitate-enhanced
GSIS, we hypothesize that the lipolytic product subsequent to DAG hydrolysis i.e.,
monoacylglycerol (MAG), but not DAG as was initially thought (Prentki and Matschinsky,
1987) is the major lipolysis-derived signal for insulin secretion. Thus, in this study, we
want to test the hypothess that MAG, generated from GL/FFA cycling, may be the
necessary signal for the lipid amplification of GSIS.
2. MATERIALS AND METHODS
2.1 Materials
Cell culture supplies were from Corning (Corning, NY) and Fisherbrand (Canada). 2-
Arachidonylglycerol was from Sigma Chemicals. WWL70 was obtained from Cayman
Chemical Company and AMG9810 was from Tocris Bioscience. Both WWL70 and
AMG9810 were dissolved in dimethylsulfoxide (DMSO) before their use in insulin
secretion experiments. D-[U-14C] glucose was from GE Healthcare (Canada) and palmitate
sodium salt was from Nu-Check Prep (Elysian, MN). The bicinchoninic acid protein assay
from Pierce (Rockford, IL) was used. Stock unlabelled palmitate was prepared at 4 mM
concentration in 5% defatted BSA as described elsewhere (Roduit et al., 2004). Orlistat was
purchased from Sigma and JZL184 was from Cayman. Antibodies were from Abcam.
2.2 Cell culture
INS 832/13 cells (Hohmeier et al., 2000) were cultured at 37°C in a humidified atmosphere
containing 5% CO2 in RPMI 1640 medium with sodium bicarbonate, supplemented with
10% (v/v) fetal calf serum (Wisent), 10 mM HEPES, pH 7.4, 2 mM L-glutamine, 1 mM
sodium pyruvate and 50 µM -mercaptoethanol (complete RPMI). Cells were grown to
80% confluence. Media were changed to RPMI 1640 containing 3 mM glucose
supplemented as the complete RPMI 24 h prior to the experiments. Insulin secretion
incubations were conducted in Krebs-Ringer bicarbonate buffer containing 10 mM HEPES,
pH 7.4 (KRBH).
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2.3 Islet isolation
All procedures were approved by the Institutional Committee for the Protection of Animals
at the Centre Hospitalier de l’Université de Montréal Research Center. Wistar rats, C57Bl6
or CD1 mice (all male) from Charles River (St-Constant, QC, Canada) were anaesthetized
with Somnotol® (MTC Pharmaceuticals, Canada) and sacrificed by exsanguination.
Pancreatic islets were isolated by collagenase (type XI from Sigma) digestion of total
pancreas (Gotoh et al., 1987), followed by separation (centrifugation at 1,040 x g) on a
Histopaque 1091 or 1077 (Sigma) gradient. Isolated islets were handpicked and cultured
overnight in a Petri dish at 37°C in a humidified atmosphere containing 5% CO2 in regular
RPMI 1640 medium with sodium bicarbonate, supplemented with 10% fetal calf serum, 10
mM HEPES pH 7.4, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/mL penicillin and
100 µg/mL streptomycin.
Human islets were obtained from the Human Islet Isolation Core of the Montreal Diabetes
Research Center, using appropriate ethical guidelines. The donors were males without any
known disease. Islets were hand-picked and cultured overnight before use. Both rodent and
human islets were also treated with trypsin to disperse islet cells and then cultured
overnight in RPMI complete medium. These overnight cultured dispersed islets cells were
then used for examining the effect of various pharmacological agents.
2.4 Insulin secretion measurement
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INS 832/13 cells were washed in KRBH containing 1 mM glucose and 0.5% defatted BSA
(KRBH 1G/0.5%BSA) and pre-incubated for 45 min in KRBH 1G/0.5%BSA in presence
of pharmacological agents (at indicated concentrations) or vehicle. For examining the effect
of WWL70 (ABHD6 inhibitor), AMG9810 (TRPV1 antagonist), orlistat (pan-lipase
inhibitor), and JZL184 (MAG lipase inhibitor), drugs were added first in pre-incubation
media and then during incubations. 2-AG was added to cells at concentrations up to 1 μM,
and other MAG species at concentrations up to 400µM. Insulin secretion from INS 832/13
cells was measured by either 45-min or 2h static incubations in KRBH containing various
glucose concentrations, 0.5% defatted BSA and pharmacological agents or vehicle, with or
without 35 mM KCl or 0.3 mM palmitate, as specified.
For insulin secretion from rat, mouse or human islets, batches of 10 islets were washed in
KRBH containing 2.8 mM glucose and 0.5% defatted BSA, and pre-incubated for 45 min
in KRBH containing 2.8 mM glucose, 0.5% defatted BSA and different pharmacological
agents (at the indicated concentrations) or DMSO. Islets were then incubated for either 45
min or 2h in KRBH containing various glucose concentrations or 2.8 mM glucose plus 35
mM KCl, 0.5% defatted BSA in the presence or absence of drugs (at indicated
concentrations) or DMSO. At the end of the incubations, media were collected and insulin
was extracted from cells or islets in acid-ethanol (1.5% HCl, 75% ethanol). Total insulin
contents and insulin released into medium were determined by radioimmunoassay using
human insulin standard (Linco Research, MO).
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2.5 Effect of Lipase inhibitors on the incorporation of [U-14C]-glucose into lipids
INS832/13 cells were incubated overnight at 11 mM [U14C]-glucose in RPMI medium in a
CO2-incubator in order to pre-label lipids in the cells. Then the cells were washed in KRBH
(1 mM [U14C]-glucose; same specific activity as with 11mM glucose) and pre-incubated
for 45 min in KRBH at 1 mM [U14C]-glucose to bring metabolism to basal level. After this,
cells were further incubated for 2h in KRBH at 1 & 10 mM [U14C]-glucose with and
without the following inhibitors: Orlistat (50 μM), WWL70 (10 μM) and JZL184 (1 μM).
Then the cells were washed rapidly with PBS, flash-frozen in liquid nitrogen and extracted
for lipids. Lipids were separated by TLC and the associated radioactivity was quantified.
Neutral lipids were separated on boric acid/silica gel-TLC, with a two dimentional two
solvent systems; first, with petroleum ether: diethyl ether: acetic acid (70:30:1); then using
a second solvent system up to half of the plates, with chloroform: acetone: acetic acid
(60:40:1). Phospholipids were separated with a solvent system of chloroform: methanol:
water (65:25:4).
2.6 LC/MS/MS measurement of MAG and DAG species
INS832/13 cells were seeded in 12-well plates at a density of 0.3 million cells per well and
cultured for 36 h. Then the cells were starved in RPMI 1640 with 10% FBS at 1mM
glucose for 2 h. Cells were then washed in KRBH with 0.5%BSA and 1mM glucose and
pre-incubated for 45 min in the same KRBH to bring metabolism to basal level. Then the
cells were further incubated for 2h in KRBH at 1 or 10 mM glucose and the indicated
inhibitors. WWL70 was used at 10 μM, where shown. Then the cells were rapidly washed
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and flash-frozen in liquid nitrogen and extracted for lipids. The lipid extracts were sent to
Kansas Lipidomics Research Center, Kansas State University for analysis by LC-MS/MS.
2.7 ABHD6 Over-expression
The pCMV-based plasmids expressing human ABHD6 and Green Fluorescent Protein
(GFP) were obtained from Origene. pCMV-AC plasmids coding for either ABHD6 or GFP
(used as control and also to monitor transfection efficiency) were introduced into
INS832/13 cells using the Amaxa Nucleofector method (Program T-27, solution V; Amaxa,
Inc., Gaithersburg, MD). Five micrograms of DNA were used for each transfection of 6
million cells. Transfection efficiency was more than 85%, as assessed by cytometry and
confocal microscopy of GFP-transfected cells. After transfection, cells were seeded in 12-
well and six-well plates for insulin secretion and Western blot analysis, respectively, and
cultured for 72 h before collecting for Western blot analysis or performing insulin
secretion experiments.
2.8 Quantitative real-time RT-PCR
Total RNA was extracted from INS 832/13 cells, islets and rodent tissues using the Rneasy
Mini kit (Qiagen) with Rnse-free Dnase (Qiagen). RNA (3 µg) was reverse transcribed to
cDNA using M-MLV reverse transcriptase (Invitrogen, Canada) and hexamers as
previously described (Delghingaro-Augusto et al., 2009). Gene expression was determined
by the standard curve method and normalized to the expression of ¦Â-actin mRNA. Real-
time PCR analysis was performed using a Rotor-Gene R3000 (Corbett Research, Australia)
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and the LCR Faststart DNA masterplus SYBR Green reagent (Roche, Canada). Primers for
MAG lipase, ABHD6 and TRPV1 were designed using Primer3 software. Results are
expressed as the ratio of target mRNA to ¦Â-actin mRNA.
2.9 Immunoblot analysis
INS 832/13 cells, islets and rodent tissues were processed for SDS-PAGE and Western
blotting. Cells or tisuses were washed with cold PBS and lysed using a lysis buffer
containing 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton
X-100, 0.1% SDS, protease inhibitors, 1 mM Na3VO4 and 2.5 mM Na4P2O7. Lysates were
sonicated, aliquots were taken for protein assay and samples were stored at -80°C. Proteins
from total cell extracts (20 µg protein) were separated on 8% SDS-PAGE and transferred to
nitrocellulose membranes (Scheicher & Schuell, Germany) for Western blotting. Blotted
proteins were probed using monoclonal antibodies (Abcam) against MAG lipase and
ABHD6 according to suppliers’ protocols. Horseradish peroxidase-conjugated goat anti-
mouse IgG (Bio-Rad, Hercules) was used as second antibody with SuperSignal West Pico
chemiluminescence (Pierce) for detection.
2.10 Cytosolic Ca2+ measurement in rat islets
Cytosolic Ca2+ was measured by adapting a previously described procedure (Jahanshahi et
al., 2009). Briefly, dispersed rat islet cells were plated on a 42 mm coverslip and incubated
overnight at 37°C in complete medium at 11 mM glucose. Cells were starved in RPMI
complete medium at 2.8 mM glucose for 2h and loaded in KRBH containing 2.8 mM
65
glucose, 1% BSA (defatted), 2.5 mM probenicid, 0.2 mM sulfinpyrazone and 6 ¦ÌM Fluo-
4AM + pluronic acid F-127 (1:1) (Invitrogen, USA) for 75 min at 37°C. Coverslips were
then mounted in a closed perifusion chamber, and cells perifused with KRBH containing
1% BSA, 2.5 mM probenicid, 0.2 mM sulfinpyrazone and 2.8 mM or 16.7 mM glucose or
2.8 mM glucose + 35 mM KCl using a syringe pump (New Era pump system). The
microscope, perifusion chamber and solutions were maintained at 37°C. Cells were
incubated for 180 s at 2.8 mM glucose and images were recorded for baseline
determination. Images were then recorded every second for a period of 10 min in the
presence of 16.7 mM glucose, and for a period of 2 min in the presence of KCl using a
Leica TCS SP5 inverted confocal microscope. Incubation with 16.7 mM glucose was
started at time 20 s, but the analyses were started at 150 s to exclude baseline fluctuations
(caused by the autofocus stabilization device of the microscope scanner and false-positive
fluorescence due to osmolarity changes in the perifusion chamber). Inhibitor of ABHD6
(WWL70, 10 μM) and of TRPV1-R (AMG9810, 10 μM) were included in the perifusion
medium at both glucose concentrations. Perifusions were conducted sequentially, with
initially 2.8 or 16.7 mM glucose alone, and then with WWL70 followed by AMG9810, in
the same perifusion chamber.
2.11 Statistical analysis
Values are expressed as means ± SEM. Statistical analysis was performed using one-way
ANOVA with Dunnett’s post-test for multiple comparisons or two-way ANOVA with
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Bonferroni’s post-test for multiple comparisons using GraphPad Prism (GraphPad
Software).
3. Results
3.1 Restoration of GSIS by MAG in INS832/13 -cells after inhibition by the lipolysis
inhibitor orlistat
Since the lipolysis inhibitor orlistat reduces GSIS, we examined if the GSIS can be restored
by the addition of MAG to -cells. We initially assessed the effect of 2-AG (1μM) in
INS832/13 cells at low and high glucose and the results indicated that the orlistat-inhibited
GSIS was almost completely restored by 2-AG (Fig. 13A) and 2-AG was able to enhance
insulin secretion even in the absence of orlistat inhibition. However, since 2-AG is a known
endocannabinoid, which may act by activating CB1/CB2 receptors, and also because CB1/
CB2 receptors were earlier implicated in GSIS (Matias et al., 2006), we checked if blocking
the CB1 receptor antagonizes the 2-AG effect. However, AM251, an antagonist of CB1-
receptor was found to have no significant influence on 2-AG mediated effects on insulin
secretion either at 2 mM or 10 mM glucose (Fig. 13A). We further ascertained that the
MAG-restoration of orlistat inhibited GSIS in INS 832/13 -cells was not specific to 2-AG
and that 1-stearoylglycerol (1-SG, 100μM), 1-palmitoylglycerol (1-PG, 100μM) were also
able to restore GSIS (Fig 13B). 1-SG and 1-PG could completely restore GSIS, inhibited by
25 μM orlistat, at 5mM glucose, and partially at 10mM glucose. Both 1-SG and 1-PG were
also found to significantly stimulate GSIS in the absence of orlistat (Fig. 13B). Thus orlistat
inhibition of lipolysis, which results in reduced formation of MAG due to the inhibition of
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TG and DAG hydrolysis, is associated with lowered GSIS and replenishing cells with
exogenous MAGs could restore secretion, suggesting that MAG is the likely mediator of
GSIS.
Figure 13 Various MAG species restore GSIS in INS832/13 cells treated with the
panlipase inhibitor orlistat. INS832/13 cells were pre-incubated in KRBH with different
MAGs without orlistat for 45 min, and then the cells were incubated at various glucose
concentrations, or at 1 mM glucose plus 35 mM KCl, with or without different MAGs, in
the absence and presence of orlistat for 45 min (A) or 2 h (B). Fig 4A shows studies using
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2-AG, orlistat and the CB1 receptor antagonist AM251 (1µM). Fig 4B shows studies using
1-SG and 1-PG. Results are means ± SE of 3 separate experiments, in triplicate wells.
3.2 Expression of MAG-lipase and ABHD6 in different tissues, islets and -cell lines:
After observing that MAG can restore GSIS inhibited by orlistat, we assessed the
expression of MAG hydrolases in -cells as there have been no studies regarding MAG
lipase expression in islets or -cells in comparison to other tissues. Expression of MAG-
lipase in different rat tissues and in islets from mouse, rat and humans as well as two beta
cell lines was examined by Western blotting and RT-PCR. Comparatively, MAG-lipase
expression in white adipose tissue was much higher at both mRNA and protein levels (Fig.
14A), while its expression is either undetectable in the beta cell lines (INS832/13 and
MIN6) and human and rat islets or much less in the mouse islets (Fig. 14A).
Expression of plasma membrane-bound ABHD6, which has been proposed as a novel
MAG lipase in brain and other tissues and hydrolyzes MAG to glycerol and FFA, was also
examined. As indicated in the Figure 14B, expression of ABHD6 was found to be highest
in liver, while its expression in INS832/13 and MIN6 cells and in mouse, rat and human
islets is also significant.
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Figure 14 Expression of MAGL (A) and ABHD6 (B) in rat tissues, islets and beta cells.
Protein and mRNA were extracted indicated in the “Materials and Methods.
3.3 The effect of inhibition of MAGL and ABHD6 on GSIS.
Hydrolysis of MAG either by MAG lipase was shown to be specifically inhibited by
JZL184 in brain (Long et al., 2009). Similarly, WWL70 was described as a specific
inhibitor of ABHD6 in brain neuronal cells, with an EC50 of 70nM (Blankman et al., 2007).
Since orlistat is a pan-lipase inhibitor, we tested the effects of specific inhibition of MAG
lipase and ABHD6 on GSIS. There was no significant change in GSIS in INS832/13 cells
incubated in the presence of JZL184 (1μM) for 2h, which is consistent with the poor
expression of MAGL in these cells (Fig 15A).
Inhibition of ABHD6 in INS832/13 cells, which is expressed at relatively higher levels than
MAG lipase, by 10μM WWL70, resulted in significantly enhanced GSIS at 5 and 10 mM
glucose (Fig. 15B). WWL70 effects on insulin secretion also occurred in the presence of
0.3mM palmitate (data not shown). Under similar incubation conditions, 25 μM orlistat
near completely inhibited GSIS. These results are compatible with the possibility that
reduction of total lipolysis by orlistat likely reduced the levels of MAGs, whereas,
inhibition of ABHD6 probably caused MAG to build-up, and that there is a reciprocal
relationship between MAG levels of -cells and GSIS.
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Figure 15 The effect of MAGL and ABHD6 inhibitor on insulin secretion in beta cells.
INS832/13 cells or mouse, rat and human islets were pre-treated with KRBH with 0.5%
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BSA, either with MAGL inhibitor JZL184, or with ABHD6 inhibitor WWL70 for 45 min,
and then the cells were treated with inhibitors at different glucose concentration as
indicated in the figures. Figure 15A shows the effect of MAGL inhibitor JZL184 on insulin
secretion in INS832/13 cells; Figure 15B shows the effect of ABHD6 inhibitor WWL70
and pan-lipase inhibitor orlistat on insulin secretion in INS832/13 cells. Figure 15C
indicates the dose-dependence effect of WWL70 on insulin secretion in INS832/13 cells;
Figure 15D indicates the effect of the inhibitor WWL70 on insulin secretion in dispersed
rat islets; Figure 15E indicated the effect of inhibitor WWL70 on insulin secretion in CD-1
mouse islets.; Figure 15F shows the effect of the inhibitor WWL70 on insulin secretion in
human islets. Results are means ± SE of 3 separate experiments. *p<0.05, **p<0.01,
***p<0.001 when compared to the corresponding DMSO group.
We then examined the dose-dependent effects of WWL70 on insulin secretion. In this
experiment, we assessed the effect of WWL70 at different concentrations (1, 2, 5, 10 & 20
μM) on insulin secretion. As indicated in the Figure 15C, WWL70 dose-dependently
increased insulin secretion at 10mM glucose, with the maximal effect at 10μM.
To further confirm the results obtained in INS832/13 cells, which are established
immortalized cells, we have checked the effect of WWL70 in mouse (Fig. 15D), rat (Fig.
15E) and human islets (Fig. 15F). Inhibition of ABHD6 by WWL70, in islets from rat,
mouse or human, also significantly stimulated insulin secretion (Fig. 15D-F), indicating
that the results seen with WWL70 in INS cells are reproducible in islets.
3.4 14C-Glucose incorporation into neutral lipids: Effect of orlistat and WWL70 at low
and high glucose concentrations
We then checked if either enhancing or inhibiting the GL/FFA cycle lipolytic segment,
respectively, with glucose or by orlistat and WWL70 in INS832/ 13 cells, results in altered
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profile of lipid molecules, in particular, MAG. INS832/13 cells were incubated as indicated
in the “Materials and Methods” under equilibrium labeling conditions. After separation of
different lipids using TLC, the associated radioactivity was quantified by software. Results
are shown as the amount of glucose used for lipid synthesis. Even though the mass of
individual lipids was not quantified directly, the radioactivity-derived results give an
approximate idea about the relative quantities of these lipid species. Consistent with
previous reports, different neutral lipids, including TG, DAG and MAG, increased with
increasing glucose concentration as shown in Figure 16A. Also there was marked TG
accumulation in the presence of orlistat, while it increased slightly in the presence of
WWL70. DAG levels did not show any significant differences due to inhibitor treatments
(Fig. 16A). The results also shows that glucose stimulation of the -cells increased both 1-
MAG and 2-MAG levels and that WWL70 further amplified the glucose effect. However,
the pan lipase inhibitor orlistat reduced the MAG levels (Fig. 16A), probably because of its
effects on ATGL, HSL and sn1-DAG lipases and increased TG content. The changes in the
MAG levels paralleled the changes in insulin secretion, indicating a possible direct
relationship between cellualar MAG content and insulin secretion.
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Figure 16 Lipid profiles measured by TLC (A) and LC-MS/MS analysis (B).
INS832/13 cells were treated as indicated in the ‘materials and methods”. Figure 16A
shows the change of different neutral lipids, including TG, DAG and MAG after treatment
with WWL70 and orlistat; Figure 16B shows the change of total MAG and each MAG
species after treatment with 1mM and 10mM glucose as well as with WWL70. *p<0.05,
**p<0.01, ***p<0.001 when compared to the corresponding glucose group.
3.5 Profile of different MAG species, measured by LC-MS/MS analysis
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INS832/13 cells were incubated as described “Materials and Methods”. Lipid extracts were
processed for LC-MS/MS for profiling MAG and DAG species. Results indicated that high
glucose concentration elevates MAG levels and the presence of ABHD6 inhibitor WWL70,
leads to much higher levels of various species of MAG (Fig. 16B). In particular, we noticed
that 1-stearoylglycerol (1-SG) is elevated quite significantly in the presence of WWL70
(Fig. 16B, right panel). We also noticed significantly elevated levels of two unknown
species of MAG. The total DAG content increased with increasing glucose concentration,
but WWL70 had relatively little further effect on DAG levels (data not shown).
3.6 The effect of exogenous MAG on insulin secretion
Inasmuch as MAG levels increased with WWL70 addition and correlated with elevated
insulin secretion, we examined whether there is any direct effect of different MAGs on
insulin secretion. In these experiments, we tested 5 different MAGs (1-stearoylglycerol, 1-
SG; 1-palmitoylglycerol, 1-PG; 1-oleoylglycerol, 1-OG; 1-linoleoylglycerol, 1-LG; 1-
arachidonoylglycerol, 1-AG; 2-oleoylglycerol, 2-OG) for their dose-dependent effects in
INS832/13 cells at 5mM glucose. Results indicated that different MAGs show varying
effects in inducing insulin secretion (Fig. 17). We found that 1-SG and 1-palmitoylglycerol
(1-PG) maximally stimulated insulin secretion, as compared to 1-OG, 2-OG and 1-LG (Fig.
17B).
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Figure 17 The effect of exogenous MAG species on insulin secretion. INS832/13 cells
were preincubated with KRBH with 2mM glucose and 0.5%BSA plus different MAGs for
45min, and then INS832/13 cells were incubated in KRBH with 5mM glucose plus
different MAGs for 2h. Results are means ± SE of 3 separate experiments, in triplicate
wells. *p<0.05, **p<0.01, ***p<0.001 when compared to the corresponding control group.
3.7 The effect of overexpression of ABHD6 on GSIS
Since the inhibition of ABHD6 in the -cells enhances GSIS, probably via augmenting the
MAG levels, we decided to examine whether overexpression of ABHD6 has opposing
effects (i.e., inhibitory) on GSIS. Overexpression of ABHD6 in INS832/13 cells
(transfected with pCMV-ABHD6 plasmid; origene) was conducted by the Amaxa
Nucleofector method (Program T-27, solution V; Amaxa, Inc., Gaithersburg, MD). The
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tranfection efficiency was evaluated to be more than 85% (data not shown) by
cotransfecting the cells with a GFP expression plasmid and by cytometry and confocal
microscopy of GFP in the transfected cells. After 72h transfection, the cells were collected
for Western blotting and insulin secretion. Results showed that ABHD6 protein level
increased about 2-fold in the cells transfected with the expression plasmid (Fig. 18A).
Overexpression of ABHD6 led to a significant decrease in both glucose stimulated and also
palmitate-amplified insulin secretion (Fig.18B). The enhanced ABHD6 activity in the
INS832/13 cells reduced GSIS, probably by lowering the MAG levels, which are elevated
in the presence of glucose and palmitate. These results support the view that MAG
mediates or is involved in the augmented insulin secretion at high glucose ± palmitate, as
overexpression of ABHD6 dampens the insulin secretion stimulating effect of high glucose
± palmitate (Fig. 18B).
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Figure 18 The effect of over-expression of ABHD6 on insulin secretion in INS832/13
cells. INS832/13 cells were transfected with Amaxa reagent. After 72h transfection, the
cells were used for Western blotting and insulin secretion. Figure 18A shows the
expression of ABHD6 by Western blotting; Figure 18B indicates the effect of over-
expression of ABHD6 on insulin secretion. Results are means ± SE of 3 separate
experiments, in triplicate wells. *p<0.05, **p<0.01, ***p<0.001 when compared to the
corresponding “GFP” group.
3.8 TRPV1 is possiblly responsible for WWL70-enhanced insulin secretion.
The foregoing results showed that MAG, generated via GL/FFA cycle, plays a pivotal role
in the lipid amplification of GSIS. However, the target of MAG in the -cell, through
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which insulin secretion is enhanced, is not known. Recently, it has been shown that MAGs
could activate TRPV1 channel and cause calcium influx (Iwasaki et al., 2008). TRPV1 is a
plasma membrane localized non-selective cation channel, which preferentially functions in
the influx of Ca2+ ions, when stimulated (Venkatachalam and Montell, 2007). Besides, it is
also known that capsaicin, which activates TRPV1, stimulates insulin secretion both in
vitro in beta cells (Akiba et al., 2004) and in vivo in ZDF rats (Gram et al., 2007). The
ligand-binding site of TRPV1 is known to be on the inner side of the plasma membrane.
Considering this, we evaluated the possible role of TRPV1 in the elevated GSIS seen due to
MAG accumulation. First, we assessed the expression of plasma membrane-bound TRPV1
in different rat tissues and mouse, rat and human islets by Western blotting and RT-PCR.
As demonstrated in Figure 19A, liver expressed maximal amount of TRPV1, while its
expression in beta cell line (MIN6 and INS832/13) and rat tissue is also quite significant.
As we noticed that -cells do express TRPV1, we employed AMG9810 (Gavva et al.,
2005), a specific antagonist of TRPV1, to check the role of TRPV1 and its activation by
MAG in insulin secretion. As shown in Figure 19B and 19C, TRPV1 antagonist,
AMG9810, could dose-dependently decrease GSIS, and this effect was more evident in the
presence of 0.3mM palmitate, indicating that TRPV1 may contribute a significant part to
the Ca2+ influx needed for insulin granule exocytosis. As MAG can activate TRPV1 and
enhance Ca2+ influx and because the MAG levels increase in the presence of glucose and
fatty acids, it is quite likely that the enhanced insulin secretion with glucose plus fatty acids
may be mediated through the accumulation MAG, which in turn activates TRPV1 channel
and thus insulin secretion. Thus the inhibitory effects of AMG9810 on insulin secretion are
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more pronounced in the presence of 10μM WWL70, which causes significant accumulation
of MAG by inhibiting ABHD6 (Fig. 19D).
In order to confirm the results seen with INS832/13 cells in primary beta cells, we also
performed similar experiments on rat islets. As indicated in the Fig 19E & 19F, AMG9810
could significantly decrease GSIS and in the presence of WWL70 this inhibitory effect was
more evident.
In order to check whether TRPV1 indeed plays a role in inducing calcium influx and thus
insulin secretion, we performed calcium measurements in dispersed rat islets with or
without WWL70 or AMG9810. There was a clear increase of calcium influx induced by
WWL70, while AMG9810 decreased calcium influx (Fig 19G). This indicates that the
enhanced insulin secretion by WWL70 is at least partially mediated by increased calcium
influx conducted by TRPV1 channel. AMG9810, an antagonist of TRPV1, decreased the
activity of TRPV1 channel, leading to reduced calcium influx and thus decreased insulin
secretion.
81
82
Figure 19 TRPV1 is responsible for WWL70-enhanced insulin secretion. The effect of
the TRPV1 receptor in glucose-stimulated and WWL70-enhanced insulin secretion was
examined using the specific antagonist AMG9810. Figure 19A indicates the expression
level of TRPV1 in different rat tissues, islets and beta cell lines; Figure 19B indicates the
effect of AMG9810 on GSIS (1mM glucose in red, 10 mM glucose in green); Figure 19C
indicates the effect of AMG9810 on GSIS in the presence of exogenous palmitate
(0.25mM); Figure 19D indicates the effect of AMG9810 on WWL70-enhanced insulin
secretion at high glucose; Figure 19E indicates the effect of AMG9810 on insulin secretion
in rat islets; Figure 19F shows the effect of AMG9810 on WWL70 enhanced insulin
secretion in rat islets; Figure 19G indicates the effect of WWL and AMG9810 in inducing
calcium influx in dispersed rat islets.Drugs were added at time 50 s and a depolarizing
concentration of KCl (30mM) at time 700 s. Results are means ± SE of 3 separate
experiments. *p<0.05, **p<0.01, ***p<0.001 when compared to the corresponding glucose
group.
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4. Discussion
Insulin secretion by the pancreatic -cell is an essential physiological process and this is
governed by various cellular, nutritional and pathological factors. Pancreatic islets secrete
insulin under normal conditions, in response to post-prandial increase in blood glucose
levels. Other fuels including amino acids like leucine and glutamine and also fatty acids
contribute to further augment insulin secretion. Even though the precise mechanism of
insulin secretion is not known, the significance of the elevated Ca2+ influx and the role of
K+-ATP channels have been well documented. Prentki group and others (Prentki and
Corkey, 1996) have provided ample evidence for the existence of a lipid amplification
pathway for enhancing GSIS and as instrumental for the second phase insulin secretion.
Recently, Prentki group has suggested that GL/FFA cycle as being an essential component
in the lipid amplification pathway of insulin secretion (Nolan et al., 2006a; Nolan et al.,
2006b; Prentki and Madiraju, 2008). Lipolysis has been shown to be important for insulin
secretion as studies showed curtailed GSIS in islets upon inhibition of lipolysis (Masiello et
al., 2002; Winzell et al., 2006). Prentki group and others provided evidence for the
involvement of HSL, which prefers to hydrolyze DAG to MAG, in the regulation of GSIS
both in vivo and in vitro (Fex et al., 2009; Peyot et al., 2004; Roduit et al., 2001). A recent
study from Prentki lab showed that ATGL, which hydrolyzes TG to DAG, in the -cells is
also necessary for fuel and non-fuel stimulated insulin secretion, both in vitro and in vivo
(Peyot et al., 2009b). Besides HSL, sn1-DAG lipase, a plasma membrane enzyme, was also
suggested to play a role in the normal GSIS (Guenifi et al., 2001; Konrad et al., 1994).
Orlistat, an inhibitor of lipolysis, is also known to antagonize fatty acid augmentation of
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GSIS in isolated islets (Nolan et al., 2006a). The exact nature of the lipid-derived signal
that is essential for lipid-amplification of GSIS is not clear, even though DAG was initially
thought (Prentki and Matschinsky, 1987) to be the major lipolysis-derived signal for insulin
secretion. However, since conditions that lead to DAG accumulation (eg., HSL ablation
and DAG-lipase inhibition) also lead to lowered GSIS, it seems plausible that
monoacylglycerol (MAG), generated from the lipolysis segment of GL/FFA cycling, likely
functions as a metabolic coupling factor in GSIS.
As inhibition of lipolysis by orlistat almost completely obliterates GSIS in -cells, we first
investigated whether MAGs could reverse this inhibitory effect of orlistat on insulin
secretion. Our initial experiments, revealed that orlistat-inhibited GSIS could be reversed
with 2-AG, which is also effective in enhancing un-inhibited GSIS. As 2-AG is an
endocannabinoid and also functions by activating CB1-endocannabinoid receptor, we
ascertained if the 2-AG effects are related to its endocannabinoid-type activity. Earlier
studies have demonstrated that 2-AG exerts both inhibitory (Juan-Pico et al., 2006) and
stimulatory (Juan-Pico et al., 2006; Matias et al., 2006) effects on insulin secretion and that
these effects are likely mediated via CB1/ CB2 receptors. Our results showed that 2-AG
enhances insulin secretion at 2mM glucose, though this effect was not significant at high
glucose concentration (10mM). We also found that unlike the earlier findings, CB1-
receptors are not involved in the 2-AG mediated effects on GSIS and the restoration of
GSIS after orlistat inhibition. Thus an antagonist of CB1 receptor, AM251 had no effect on
2-AG mediated increase in insulin secretion. Since 2-AG could reverse the inhibition of
orlistat on insulin secretion, indicating MAG may be the putative metabolic coupling factor,
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we tested whether other MAGs could also have similar effect. We noticed that two other
MAGs, 1-SG and 1-PG could also completely restore insulin secretion after orlistat
inhibition at intermediate glucose (5mM glucose) and partially at high glucose (10mM
glucose). These results suggested that inhibition of lipolysis probably reduces the
production of MAG, which likely acts as a lipid signal for augmenting GSIS, as exogenous
supply of MAG restores the orlistat-inhibited insulin secretion.
To further test the hypothesis of MAG as a novel MCF, we decide to employ
pharmacological and molecular biological methods to alter the MAG levels inside the cells.
In order to achieve this, it was necessary to know the expression of different MAG lipases
in the beta cells. Expression of MAG lipases in -cells or islets was not reported before.
The classical MAG lipase has been identified more than 40 years ago, and many reports
have demonstrated that MAGL is highly expressed in adipocytes. Western blotting and RT-
PCR analyses to detect the MAGL in different tissues and mouse, rat and human islets as
well as two beta cell lines, MIN6 and INS832/13 revealed that adipocytes have high
MAGL expression whereas, it is not expressed to any significant extent in beta cells (Fig.
14 A). Besides the classical MAGL, two other plasma membrane proteins with MAG lipase
activity, viz., ABHD6 and ABHD12 were identified in the brain, and these enzymes were
found to contribute to 15% of the total MAG hydrolytic activity in the brain (Blankman et
al., 2007). Recent reports indicated that ABHD6 controls the accumulation of 2-AG and
thus its availability to cannabinoid receptors in brain (Marrs et al., 2010). ABHD6 is an
integral membrane protein with its active site facing the cytosolic side where as ABHD12
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has its active site facing towards exterior of the cell (Blankman et al., 2007). As indicated
in Fig 14B, ABHD6 is ubiquitously expressed in all sources of beta cells, including mouse,
rat and human islets as well as beta cell lines, MIN6 and INS832/13. Expression of
ABHD12 at protein level could not be ascertained with certainty due to the poor quality of
antibody, even though its mRNA level could be easily detected (data not shown). These
results indicated that ABHD6 may be the enzyme responsible for MAG hydrolysis and in
controlling MAG levels in beta cells.
We then examined the effect of two specific inhibitors for MAGL and ABHD6, viz.,
JZL184 and WWL70, respectively, on insulin secretion. Inhibition of MAGL with JZL184
has no effect on insulin secretion (Fig. 15A) and this is in accordance with the poor
expression of MAGL in -cells. However, ABHD6 inhibitor- WWL70 caused a robust
increase in insulin secretion (Fig. 15B), indicating that MAGs build-up inside the cells only
upon inhibition of ABHD6, and thus leads to the enhanced insulin secretion. As a control
we also included orlistat, which can reduce the production of MAGs by inhibiting lipases,
showed strong inhibition of insulin secretion. WWL70 could dose-dependently increase
insulin secretion (Fig. 15C), with the maximum effect being observed at 10μM. In order to
confirm the results seen with INS cell line, we performed similar experiments in a more
physiological beta cell model, i.e., isolated islets, from mouse, rat and human donors. In the
islets from all the three species WWL70 could enhance GSIS (Fig. 15D, 15E and 15F),
which confirmed the results obtained with INS832/13 cell line. These results provided
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further support for the view that MAG, whose levels are regulated by the activity of
ABHD6, likely mediates the lipid amplification of GSIS.
In order to ascertain that the effects of WWL70 are metabolism-dependent rather than
direct membrane depolarization effects, we tested the effect of this drug on KCl induced
insulin secretion. At low glucose concentration (1 mM), a large excess of KCl (35 mM)
leads to plasma membrane depolarization and Ca2+ influx, which promotes the fusion of
insulin granules that are already docked at the membrane. Thus this process bypasses the
need for either K+ATP channels or other receptors for Ca2+ influx. WWL70 did not show any
effect on KCl-stimulated insulin secretion in INS832/13 cells. This supports the notion that
MAG that accumulates due to WWL70 inhibition of ABHD6 is needed for insulin secretion
and high KCl bypasses this metabolism-based mechanism. Interestingly, stimulation of
insulin secretion by amino acids, glutamine + leucine at low glucose, is also enhanced by
WWL70, similar to GSIS. Thus, since the amino acid-stimulated insulin secretion also
involves metabolism dependent signal generation, accumulation of MAG by WWL70 can
further augment this process. We did not notice significant insulin secretion in response to
arginine in INS832/13 cells.
In order to examine whether the effects of WWL70 and orlistat on insulin secretion are
related to the altered levels of intracellular lipids, particularly MAG, we have tested the
effect of these inhibitors on MAG accumulation and insulin secretion in INS832/13 -cells.
We noticed that under conditions where all the internal lipid carbons are eqilibrium-labeled
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by [U-14C]-glucose, incubation with 10 mM glucose led to increased synthesis of neutral
lipid species including triglycerides, DAG and 1- and 2-MAG and also enhanced the amount
of 14C-FFA released into the medium (not shown). Results also showed that TG accumulated
in the presence of orlistat, while ABHD6 inhibition by WWL70 only had marginal effect on
TG accumulation (figure 16). Neither of the inhibitors had any effect on total DAG levels
(including both 1,2- and 2,3-isomers). 2-MAG is formed mostly by the hydrolysis of DAG.
Interestingly, while orlistat showed no effect on 2-MAG levels, inhibition of ABHD6
(WWL70) caused a modest elevation of this lipid (Fig. 16A). If DAG and MAG are in rapid
equilibrium, it is possible that high concentration of orlistat (50 ¦ÌM) used in this experiment,
could have maintained the steady-state level of 2-MAG, by inhibiting both its formation and
degradation. On the other hand, orlistat significantly reduced the formation of 1-MAG, while
inhibition of ABHD6 by WWL70 caused a significant increase. Considering that significant
amount of the 1-MAG can also arise from the hydrolysis of LPA by lysophosphatidate
phosphatase (LPP) isoenzymes, that are not known to be inhibited by orlistat, it is surprising
that orlistat significantly lowered the production of 1-MAG. Whether there are any orlistat-
sensitive pathways of 1-MAG production in -cells, including the possible interconversion
of 2-MAG to 1-MAG, needs to be examined. It is also important to consider that the intra-
cellular location of MAG (either 1-MAG or 2-MAG) accumulation may vary depending
upon the enzyme that is inhibited, i.e., MAGL or ABHD6. This may have relevance for the
signaling functional ability of the accumulating MAG in a given cell. Thus, inhibition of the
plasma membrane associated ABHD6 by WWL70 led to a significant increase in 1-MAG,
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which is accompanied by a marked decline in the efflux of labeled FFA from INS832/13 -
cells (data not shown.
In order to know which specific MAG was increased after WWL70 treatment, we performed
LC/MS/MS to separate different MAGs and DAGs. Total MAG and DAG levels increased
in INS832/13 -cells with increasing glucose concentration in the absence of FFA,
indicating glucose could activate GL/FFA cycling, leading to elevated MAG production. In
the presence of WWL70 with high glucose, the total MAG levels are increased significantly
and there is only a modest change in total DAG levels (Fig. 16B), indicating that the
inhibitor acts on the right target. The MAG profiles indicated that several MAG species
increase at high glucose concentration, and with WWL70, there is a specific increase in 1-
SG by several fold. Thus after treatment with WWL70, which blocks the ABHD6-mediated
hydrolysis of MAG, there is a build-up of 1-SG in the -cells, which perhaps triggers insulin
granule exocytosis.
In order to further assess the role of MAG in insulin secretion, we checked whether
exogenous MAG could induce insulin secretion. As shown in the Fig 17, various exogenous
MAGs could increase insulin secretion in INS832/13 cells in a dose-dependent manner.
Among the MAGs tested, 1-SG and 1-PG showed the strongest effect in inducing GSIS,
which is highly consistent with the results of LC-MS/MS, which showed maximal
accumulation of 1-SG after WWL70 treatment. We ruled-out the possibility that the added
MAG is first converted to DAG in order to exert its effects on GSIS. Thus the inclusion of a
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specific DAG-lipase inhibitor, RHC80267, which causes a build-up of 1,2-DAG in the cells,
strongly inhibited GSIS and this inhibition is alleviated by the addition of 1-PG or 1-SG
(data not shown).
Since the above-mentioned pharmacological approach clearly indicated the importance of
ABHD6 in the regulation of GSIS, we attempted molecular biological methods to control the
expression of this protein. First we tried to knockdown ABHD6 expression using specifc
RNAi (Ambion). We noticed that even though the mRNA level of ABHD6, as measured by
RT-PCR, at different time points (24h, 48h, 72h and 96h), showed ~80% decrease (data not
shown); a corresponding decrease in the ABHD6 protein level was not seen, as assessed by
Western blotting. In spite of many efforts, we were unable to see any significant decrease in
the ABHD6 protein level, by RNAi-approach. We believe that this is due to the fact that the
mRNA level of ABHD6, is quite high, about 1/5 of that of actin, because of which even if
the ABHD6 mRNA decreases by 85% by RNAi, the remaining 15% is enough to make
sufficient ABHD6 protein and hence no change in protein level. Another problem is related
to ABHD6 being a plasma membrane protein, which generally has a longer half-life. It has
been reported that the half-life of plasma membrane proteins can be longer than 4 days. This
is a general problem for using RNAi to knockdown the membrane proteins. In our
experiments, we did not measure the half-life of ABHD6, but at least this can be one of the
reasons for the absence of a significant effect of RNAi on ABHD6 protein.
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We next examined the effect of ABHD6 over-expression, using an expression plasmid
(Origene) and a control protein (GFP) expression plasmid. As shown in Fig 18A, after 72h
transfection, there is about 2 fold increase in the ABHD6 protein level. This is not a large
increase compared to the over-expression of GFP in the controls and this may be because of
the natural presence of relatively huge amount of ABHD6 mRNA in these cells. Thus, an
additional increase in the mRNA content might have not led to a significant increase in the
protein level. Interestingly, the 2-fold over-expression of ABHD6 decreased GSIS and the
palmitate enhanced GSIS also compared with the GFP transfected control (Fig 18B). These
results strongly implicated MAG, a substrate of ABHD6, as a MCF in the process of
glucose-stimulated. Over-expresison of ABHD6 likely decreased the levels of MAG, thus
lowered the insulin secretion.
One of the possible mechanisms, by which MAG induces insulin secretion, is probably via
the activation of TRPV1 receptor. TRPV1 receptor, also known as vanilloid receptor is
activated by various agents including H+ ions, anandamide, capsaicin, heat etc. (Suri and
Szallasi, 2008; Venkatachalam and Montell, 2007; Vriens et al., 2009). The presence of
TRPV1-receptor in pancreatic -cells has been investigated by different groups and while
its presence and functionality has been shown in normal rat islet -cells (Akiba et al., 2004;
Barbasa and Fleig, 2008), studies done on ZDF rats (Gram et al., 2007) and in the Type-1
diabetes model, NOD mice (8 week old with insulinitis) (Razavi et al., 2006) were unable
to show the TRPV1-R presence in the islets. It has been demonstrated that TRPV1-R has its
92
ligand/ agonist binding site intracellularly and its activation by capsaicin or other agonists
leads to Ca2+ influx (Vriens et al., 2009), which is a pre-requisite for insulin granule fusion
with plasma membrane for exocytosis. Because of the uncertainty regarding TRPV1-R
localization in -cells, we have conducted a systematic screening of islets and INS832/13
-cells employing qRT-PCR and also Western blot analysis in the same samples. Our
results demonstrated the expression of TRPV1-R at both mRNA as well as protein level
(Fig 19A) in islets and in INS cells. Activation of TRPV1-R by capsaicin both in vitro
(Akiba et al., 2004; Barbasa and Fleig, 2008) and also in vivo has been shown to elevate
insulin secretion and Ca2+ influx (Alevizos et al., 2007; Gram et al., 2007; Moesgaard et al.,
2005). Both 1- and 2-MAG have recently been shown to activate TRPV1-R in vitro leading
to Ca2+ influx and also in vivo (Iwasaki et al., 2008). Since we found that TRPV1-R is
expressed in islets and -cells, we examined whether this receptor is involved in the
augmentation of GSIS under conditions of MAG accumulation, such as ABHD6 inhibition
by WWL70, by employing a highly specific TRPV1-R antagonist, AMG9810 (Gavva et al.,
2005). We noticed that even though AMG9810 showed a dose-dependent inhibitory effect
on GSIS, this effect is only marginal (though statistically significant) in INS cells at
intermediate and high glucose concentrations (Fig. 19B and 19C). However, AMG9810
inhibition is more marked under conditions when GSIS is enhanced by WWL70 (Fig. 19D).
Presence or absence of palmitate during GSIS incubations had no influence on AMG9810
inhibition. It is important to note that AMG9810 does not inhibit GSIS completely, even at
high concentrations, which suggests that the TRPV1-R in -cells only partially contributes
to the total Ca2+ influx needed for exocytosis. It has been suggested that in islet -cells,
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while the 1st phase insulin secretion is coupled to L-type Ca2+ channels, the 2nd phase
secretion is probably coupled to R-type Ca2+ channels (Jing et al., 2005; Pedersen and
Sherman, 2009).
It has been reported that TRPV1-KO mice (C57Bl6J genetic background) are relatively
resistant to high-fat diet induced obesity (Motter and Ahern, 2008) and also that these mice
exhibit much better glucose tolerance and insulin sensitivity (Razavi et al., 2006). Also
TRPV1-KO mice have reduced insulinemia unlike their controls, which have the tendency to
show poor glucose tolerance. However, these effects were attributed primarily to the loss of
TRPV1 in peripheral neurons in the islets (Razavi et al., 2006). Considering that activation
of TRPV1-R by its ligands capsaicin and resiniferatoxin (Gram et al., 2005; Moesgaard et al.,
2005) in vivo elevates plasma insulin levels and that deletion of TRPV1-R reduces plasma
insulin along with the present observations that TRPV1-R is indeed expressed in islets and
-cells and has a role in insulin secretion in vitro and ex vivo, strongly indicate that this
receptor in -cells may have an important function in vivo to regulate insulin secretion.
Thus collectively our results support the concept that ABHD6 is an important regulator of
GSIS and its selective inhibition causes accumulation of MAG, which activates TRPV1-R
and thereby promotes insulin secretion. Therefore, compounds that selectively target
ABHD6 have the potential to be developed as diabetes therapeutics, which increase
circulating insulin levels. Such drugs may also have the potential to increase insulin
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sensitivity in the peripheral tissues by TRPV1-R activation, as administration of capsaicin
was shown to decrease insulin resistance.
5. Conclusion
5.1 Conclusion
Collectively our results support the concept (Fig. 20) that ABHD6 is an important regulator
of GSIS and its selective inhibition causes accumulation of MAG, which activates TRPV1-
R and thereby promoting Ca2+ influx and insulin secretion. Therefore, compounds that
selectively target ABHD6 have the potential to be developed as diabetes therapeutics,
which increase circulating insulin levels. Such drugs may also have the potential to increase
insulin sensitivity in the peripheral tissues by TRPV1-R activation, as administration of
capsaicin was shown to decrease insulin resistance.
5.2 Perspective
Our results demonstrate that MAG stimulates insulin secretion via TRPV-1 activation. But
whether the effect of MAG is mediated only through this TRPV1 pathway or other possible
mechanisms exist is still unknown. In some recent work, protein kinase-D (PKD) has been
shown to associate with TRPV1 and also to phosphorylate TRPV1. Besides, PKD has been
shown to contain the DAG-binding C1-domain and to be necessary for proper GSIS. We
speculate that the C1-domain in PKD may also bind with MAG (Fig. 20), causing its
activation and thus contributing to elevated insulin secretion. These studies are presently
ongoing in our lab.
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Furthermore, DAG was shown to bind with the C1-domain of MUNC13-1, an exocytosis-
related protein, to stimulate insulin secretion. However, it has been reported that the C1-
domain of MUNC13-1 has much lower affinity for DAG, owing to an overlapping Trp
residue in the binding pocket, thus making this binding less efficient (Shen et al., 2005).
We speculate that MAG may bind with the C1-domain of MUNC13-1 more effectively
than DAG and thus able to activate this protein better to achieve insulin granule exocytosis
with higher efficiency. We are currently conducting experiments related to MAG binding
with C1-domain of MUNC13-1 with NMR (Fig. 20).
Because of the close relationship between MAG and ABHD6, we are presently generating
ABHD6 whole-body and beta-cell-specific knockout mice, to further clarify the role of
MAG as a new MCF and ABHD6 in insulin secretion and glucose homeostasis.
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Figure 20 Lipolysis-derived MAG as a MCF for insulin secretion, targeting TRPV1
channels, PKD and Munc13-1. MAG, produced either by lipolysis on lipid droplets or
due to signaling events on plasma membrane, can bind and activate on the cytosolic side: 1),
TRPV1, which is a Ca2+ channel, 2), Munc13-1, which is an effector protein of exocytosis
and 3), PKD, which is involved in the overall process of insulin granule exocytosis.
Activation of these three essential components of exocytosis will lead to elevated insulin
secretion. Thus, inhibition of ABHD6 by WWL70 can cause a build up of MAG near the
plasma membrane and cause enhanced insulin secretion, by activating TRPV1 and
promoting Ca2+ influx, which is blocked by TRPV1 antagonist, AMG9810. Besides TRPV1,
Munc13-1 and PKD may also be the targets of MAG and contribute to insulin secretion.
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